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Herpes simplex virus (HSV) entry requires four essential glycoproteins (gD, gH/gL, and gB) to enable fusion
between the virion envelope and the cellular membrane. The fusion cascade is activated by gD binding to one
of its receptors, nectin-1 or HVEM. Glycoprotein B (gB), a class III viral fusion protein, mediates the fusion
reaction, while data indicates that gH/gL acts as a regulator of gB. gB is trimeric and has a 773 amino acid
ectodomain with a highly hydrophobic membrane proximal region (MPR) (residues 731-773) and two fusion
loops (FL) per protomer. The post-fusion structure of gB was solved from the gB(730t) construct, which is
truncated to remove the hydrophobic MPR residues. In this dissertation I investigated the MPRs influence on
gBs ability to interact with membranes. I hypothesize that the MPR regulates fusion loop exposure by
interacting with the fusion loops and masks them until fusion begins. To investigate this process I constructed
a series of MPR deletion, truncation, and point mutations using both full-length mammalian expression
vectors and purified baculovirus expressed protein. I found that deletions in the MPR from full-length gB
resulted in a disruption in cell surface expression in transfected cells. This suggests the MPR is necessary for
proper folding or transport of gB. Soluble gB MPR truncations [gB(759t), gB(749t), gB(739t)] were
expressed and purified using the baculovirus expression system, and compared to MPR-less gB(730t) and full
MPR containing gB(773t). I found that gB containing an MPR segment were all compromised in their ability
to bind liposomes in comparison to gB(730t), which lacks any MPR residues. Supporting our hypothesis we
found that residues 731 to 739 were sufficient prevent liposome association and mutation of two aromatic
residues, F732 and F739, to alanine in gB(739t) restored gBs ability to bind liposomes. Together, my data
suggests the MPR does indeed regulate gBs ability to associate with liposomes, and that aromatic residues in
the MPR are important for this function. This supports our model that the MPR masks the gB FLs to prevent
premature membrane association and adds another layer of regulation to the HSV entry cascade.
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ABSTRACT 
 
DEFINING A REGULATORY ROLE FOR THE HSV GLYCOPROTEIN B 
MEMBRANE PROXIMAL REGION IN MEMBRANE ASSOCIATION 
Spencer S. Shelly 
Roselyn J. Eisenberg 
Gary H. Cohen  
 
Herpes simplex virus (HSV) entry requires four essential glycoproteins (gD, gH/gL, and 
gB) to enable fusion between the virion envelope and the cellular membrane.  The fusion 
cascade is activated by gD binding to one of its receptors, nectin-1 or HVEM.  
Glycoprotein B (gB), a class III viral fusion protein, mediates the fusion reaction, while 
data indicates that gH/gL acts as a regulator of gB.  gB is trimeric and has a 773 amino 
acid ectodomain with a highly hydrophobic membrane proximal region (MPR) (residues 
731-773) and two fusion loops (FL) per protomer.  The post-fusion structure of gB was 
solved from the gB(730t) construct, which is truncated to remove the hydrophobic MPR 
residues.  In this dissertation I investigated the MPRs influence on gBs ability to interact 
with membranes.  I hypothesize that the MPR regulates fusion loop exposure by 
interacting with the fusion loops and masks them until fusion begins.  To investigate this 
process I constructed a series of MPR deletion, truncation, and point mutations using 
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both full-length mammalian expression vectors and purified baculovirus expressed 
protein.  I found that deletions in the MPR from full-length gB resulted in a disruption in 
cell surface expression in transfected cells.  This suggests the MPR is necessary for 
proper folding or transport of gB.  Soluble gB MPR truncations [gB(759t), gB(749t), 
gB(739t)] were expressed and purified using the baculovirus expression system, and 
compared to MPR-less gB(730t) and full MPR containing gB(773t).  I found that gB 
containing an MPR segment were all compromised in their ability to bind liposomes in 
comparison to gB(730t), which lacks any MPR residues.  Supporting our hypothesis we 
found that residues 731 to 739 were sufficient prevent liposome association and mutation 
of two aromatic residues, F732 and F739, to alanine in gB(739t) restored gBs ability to 
bind liposomes.  Together, my data suggests the MPR does indeed regulate gBs ability to 
associate with liposomes, and that aromatic residues in the MPR are important for this 
function.  This supports our model that the MPR masks the gB FLs to prevent premature 
membrane association and adds another layer of regulation to the HSV entry cascade.  
 
 
 
 
 
  
	  
	  
	  
vi	  
TABLE OF CONTENTS 
Page 
DEDICATION ............................................................................................................... ii  
ACKNOWLEDGEMENTS ......................................................................................... iii  
ABSTRACT ................................................................................................................... iv  
TABLE OF CONTENTS ............................................................................................. vi 
LIST OF TABLES ...................................................................................................... viii 
LIST OF ILLUSTRATIONS ....................................................................................... ix 
CHAPTER 1:  GENERAL INTRODUCTION ............................................................1  
 A.  Herpesvirus overview ...........................................................................................1  
 B.  Virion structure .....................................................................................................4  
 C.  HSV replication cycle ...........................................................................................5  
 D.  Viral entry strategies .............................................................................................9  
 E.  Viral fusion proteins ............................................................................................11  
 a.  Class I .......................................................................................................12  
 b.  Class II .....................................................................................................16 
 c.  Class III ....................................................................................................17 
 F.  Herpesvirus entry .................................................................................................20  
 a.  gC .............................................................................................................24  
 b.  gD .............................................................................................................24 
 d.  gH/gL .......................................................................................................27  
 G.  HSV Glycoprotein B ...........................................................................................28  
	  
	  
	  
vii	  
 a.  gB functional regions ...............................................................................33  
 H.  Membrane Proximal Region ...............................................................................35  
 I.  Aims of present work ...........................................................................................39 
 J.  References ............................................................................................................42 
CHAPTER 2:  The membrane-proximal region (MPR) of HSV gB regulates  
 association of the fusion loops with lipid membranes .........................................64  
 A.  Abstract ...............................................................................................................65 
 B.  Introduction .........................................................................................................66  
 C.  Materials and Methods ........................................................................................69  
 D.  Results .................................................................................................................75 
 E.  Discussion............................................................................................................91 
 F.  References ............................................................................................................95  
CHAPTER 3:  GENERAL DISCUSSION ...............................................................105  
APPENDIX:  Autophagy is an essential component of Drosophila immunity  
 against vesicular stomatitis virus .........................................................................115
 A.  Abstract .............................................................................................................116  
 B.  Introduction .......................................................................................................117  
 C.  Materials and Methods ......................................................................................119  
 D.  Results ...............................................................................................................123  
 E.  Discussion..........................................................................................................148 
 F.  References ..........................................................................................................153 
 G.  Supplemental Data ............................................................................................162 
	  
	  
	  
viii	  
LIST OF TABLES 
 
CHAPTER 1 
Table I-1.  Human herpesvirus classification ...................................................................3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
	  
	  
	  
ix	  
LIST OF ILLUSTRATIONS 
CHAPTER 1 
Figure I-1.  Structure of the HSV-1 virion ........................................................................2  
Figure I-2.  Class I, II, III fusion proteins .......................................................................13  
Figure I-3.  Model of membrane fusion ..........................................................................14  
Figure I-4.  Entry proteins of human herpesviruses ........................................................22 
Figure I-5.  Routes of HSV entry ....................................................................................23  
Figure I-6.  Proteins required for HSV entry ..................................................................26 
Figure I-7.  Structure of HSV gB ....................................................................................30  
Figure I-8.  gB functional regions ...................................................................................34 
Figure I-9. gB membrane proximal region .....................................................................40  
 
CHAPTER 2 
Figure 2-1.  gB trimer surface representation/MPR deletions and truncations ...............77  
Figure 2-2.  Characterization of gB MPR deletion mutants ...........................................80  
Figure 2-3.  Soluble gB MPR-containing protein expression .........................................82  
Figure 2-4.  Liposome binding assay ..............................................................................84  
Figure 2-5.  Gel filtration/size exclusion chromatography .............................................87  
Figure 2-6.  Model of a possible interaction between the gB fusion loops and MPR ....90  
 
CHAPTER 3 
Figure 3-1.  Model of HSV gB pre-fusion to post-fusion conformational change .......107  
 
APPENDIX 
Figure A-1.  VSV infects Drosophila cells ...................................................................126  
Figure A-2.  Autophagy is antiviral in Drosophila cells ..............................................129 
	  
	  
	  
x	  
Figure A-3.  VSV infection activates autophagy independent of replication ...............133 
Figure A-4.  VSV infection induces autophagy in Drosophila cells ............................137 
Figure A-5.  VSV infection induces autophagy in primary cells and in adult flies ......140 
Figure A-6.  Autophagy is antiviral in adult flies .........................................................143 
Figure A-7.  The PI3K-Akt pathway controls autophagy and viral replication ............149 
Figure A-S1.  dsRNA against autophagy genes ............................................................162 
Figure A-S2.  Schneider cells were infected with VSV-gfp .........................................164 
Figure A-S3.  Purified viral components reveal VSV G is the PAMP .........................165 
Figure A-S4.  Depletion of autophagy in adult flies .....................................................166 
Figure A-S5.  Autophagy controls VSV but not DCV infection in adult flies .............167 
Figure A-S6.  Atg18-depleted flies have wild-type numbers of hemocytes .................168 
Figure A-S7.  Flies carrying a heat shock-inducible Gal4 ............................................169 
Figure A-S8.  Heterozygous ATG1 mutants carry wt levels of VSV ...........................170 
 
 
 
 
 
 
 
 
 
 
 
 
	   1	  
CHAPTER 1 
GENERAL INTRODUCTION 
Herpesvirus overview 
The viral family Herpesviridae consists of over 200 members infecting nearly 
every species of animal (39).  Herpesviridae family members are traditionally classified 
on the basis of virion architecture. They contain an electron-opaque core of double-
stranded DNA surrounded by an icosadeltahedral capsid.  The capsid is surrounded by a 
proteinaceous tegument and is surrounded by an envelope spiked with glycoproteins 
(Figure I-1) (39, 143).  There are eight known human herpesviruses (Table I-1), which 
along with all herpesviruses are further divided into three subfamilies, alphaherpesvirus, 
betaherpesvirus, and gammaherpesvirus.  These subdivisions are based on genome 
organization, biological properties, and cellular tropism.  Alpha-herpesviruses have a 
broad host range, wide cellular tropism, a short replication cycle, destroy infected cells, 
and infect sensory ganglia where latency is often established.  The human 
alphaherpesviruses include varicella zoster virus (VZV) and Herpes simplex virus type 1 
and type 2 (HSV-1 and HSV-2) (39).  The betaherpesviruses have long replication cycles 
and infect secretory glands and lymphoreticular cells. Betaherpesvirus infected cells 
become enlarged and are known as cytomegalia, and the human viruses include human 
cytomegalovirus (HCMV), human herpes virus-6 (HHV-6), and human herpes virus-7 
(HHV-7) (39).  T-lymphocytes or B-lymphocytes are the usual target cells of the 
gammaherpesviruses, which have the most restricted host range of the three herpesvirus 
subfamilies. The gammaherpesviruses infecting humans include Epstein Barr virus 
(EBV) and Kaposi’s sarcoma associated herpesvirus (KSHV) (39).   
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Figure I-1. Structure of HSV-1 virion.  The icosahedral capsid (cyan) contains the 
dsDNA genome, and is surrounded by the tegument layer (orange, portions removed).  
The tegument is surrounded by the host-derived lipid bilayer (blue), which is studded 
with the viral glycoproteins (yellow).  Adapted from Grunewald et al (48). 
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Abbrev. Vernacular name Designation Subfamily 
HSV-1 Herpes simplex virus 1 HHV-1 α 
HSV-2 Herpes simplex virus 1 HHV-2 α 
VZV Varicella-zoster virus HHV-3 α 
EBV Epstein-Barr virus HHV-4 γ 
CMV Cytomegalovirus HHV-5 β 
HHV-6 Human herpesvirus 6 HHV-6 β 
HHV-7 Human herpesvirus 7 HHV-7 β 
KSV Kaposi’s sarcoma-associated herpesvirus HHV-8 γ 
 
 
Table I-1.  Human herpesvirus classification.  The eight human herpesvirus are listed 
above with their vernacular name, official designation, and herpesvirus subfamily 
classification. Adapted from Fields Virology (39). 
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HSV-1 and HSV-2 are prevalent in the United States with seroprevalence of 58% 
and 17% of the adult population respectively (148).  HSV-1 is the oral form of the virus 
and typically causes lesions of the oral mucosa.  The genital form, HSV-2, causes lesions 
of the genital tissues.  Closer analysis of HSV-2 seroprevalence in the U.S. reveals 
women are infected at twice the rate of men, 23.1% versus 10.9% (148).  In those 
infected HSV establishes a latent infection in sensory ganglia that persists for the lifetime 
of the host (39).  HSV symptoms are rarely life threatening but cause varying degrees of 
morbidity.  Active HSV infection in immunocompetent adults can range from being 
asymptomatic to the formation of oral or genital mucosal lesions (131).  HSV can cause 
corneal infections resulting in keratitis and rarely blindness or fatal encephalitis in 
healthy individuals.  Infection of neonates and the immunocompromised can result in 
disseminated HSV that is life threatening (131).  Approximately 1500 cases of neonatal 
disseminated HSV are diagnosed each year in the United States (28) with a mortality rate 
of 47% (144).   
 
Virion structure 
Four compartments make up the HSV virion, which are the genome, capsid, 
tegument, and envelope with glycoproteins (Figure I-1) (48, 140).  HSV is a large, 
enveloped virus with a diameter of 125-200 nm and contains an approximately 150 
kilobase pair linear double-stranded DNA with a G + C content of nearly 68% (39).  The 
genome contains two covalently linked segments, called the long (L) and short (S) unique 
segments, which are linked by inverted repeats. The repeats allow rearrangement of the 
	  
	  
	  
5	  
unique sequences yielding four possible genome arrangements (53).  The HSV genome 
encodes at least 70 polypeptides (39). 
 The HSV genome is enclosed by an icosahedral capsid made from four major 
components (VP5, VP19C, VP23, VP26) and has been resolved by electron microscopy 
in detail (152).  VP5 is the major capsid protein, which oligomerizes to form ring-shaped 
capsomers, while one VP19C and two VP23 molecules form timers. VP26 is located at 
tips of the capsomers (39).  
The capsid is surrounded by the closely associated tegument layer, which is made 
of at least 22 proteins (140).  Tegument proteins have multiple roles immediately upon 
virus entry.  These functions include virion host shut-off (vhs) by UL41 to halt host 
protein synthesis (85). VP16 is an essential viral transcription factor and US11 prevents 
the shutdown of protein synthesis by protein kinase R (PKR) (2, 106).  
A lipid bilayer surrounds the genome, capsid, and tegument known as the viral 
envelope.  The envelope is derived from host lipid membrane and contains eleven 
glycoproteins (gB, gC, gD, gE, gG, gH, gI, gJ, gL, gM, gN) and at least three non-
glycosylated proteins (39). While five of these glycoproteins (gD, gB, gH, gL, gC) are 
involved in entry four (gD, gB, gH, gL) are necessary and sufficient for the fusion with 
susceptible cell membranes (55, 105). Glycoprotein C has dual functions including a 
dispensable role in viral attachment and in immune evasion blocking the complement 
pathway (57, 59, 83).    
 
HSV replication cycle 
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 HSV transmission occurs through epithelial mucosa of the human host, usually by 
direct contact between infected and uninfected tissues.  The steps of infection include 
viral attachment to the cell surface followed by fusion of the viral and cellular 
membranes allowing viral entry (122).  Viral replication occurs at the site of entry 
leading to cell death and viral spread to innervating axons of the peripheral nervous 
system.  Retrograde transport along microtubules carriers the viral capsid with tegument 
proteins to the neurons cell body and nucleus (32).  Several tegument proteins, VP16 and 
US11, are important to shutdown host synthesis and viral protein production as discussed 
above.   
Lytic infection of sensory neurons leads to destruction of the neuron, but often a 
latent infection is established where the virus persists without neuronal destruction.  In 
the sensory neurons life-long latent infection is established in the trigeminal or superior 
cervical ganglion for HSV-1 and the sacral ganglia for HSV-2 (93).  During latent 
infection the virus is protected from the host immune response in the immune privileged 
neuronal site and the low level of HSV transcription.  The latent HSV genome exists as a 
circularized extrachromosomal episome in the neuronal nucleus, and only one viral 
transcript called the latency associated transcript (LAT) is detectable in the cell (15).  In 
an incompetently understood process the latent virus can response to stimuli like stress or 
UV light and reactivate to produce infectious particles.  Reactivation leads to viral capsid 
formation and anterograde transport down the axon to the axonal termini where virions 
are assembled (93, 135).  Ultimately a secondary lytic infection of the epithelial mucosa 
occurs near the area of the previous primary infection with lesion formation or 
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asymptomatic viral shedding (91, 93).  To complete this complex replication cycle HSV 
infects multiple cell types, and this correlates with the wide cellular tropism exhibited by 
the virus in tissue culture.  
 HSV has the ability to infect epithelial, endothelial, fibroblasts, and neurons in its 
human host (39).  HSV also non-productively infects monocytes and T cells (107).  In 
vitro HSV infects most cell types tested, which is likely due to its ability to use multiple 
cellular receptors. 
As described above, attachment is mediated by envelope glycoproteins, and four 
glycoproteins (gD, gB, gH, gL) are necessary and sufficient for attachment and fusion 
with susceptible cell membranes (55, 105).  The details of viral entry and membrane 
fusion process will be discussed below.  HSV fuses either at the cell membrane or 
undergoes endocytosis and fuses with an endocytic vesicle releasing the viral capsid into 
the cytoplasm.  The capsid binds to the retrograde molecular motor dynein and is 
transported along microtubules to the nuclear pore (32, 33, 35).  Viral DNA is then 
released into the nucleus were it circularizes forming an extra-chromosomal episome.  
Expression of HSV genes products is highly regulated cascade using the cellular 
RNA polymerase II (109).  Three groups of genes have been defined based on the timing 
of there expression:  immediate-early (IE), early (E), and late (L) (39).  Generally, the 
immediate-early genes serve regulatory functions, the early genes participate in 
translation and DNA replication, and late genes are structural proteins.  Activation of IE 
gene transcription requires the presence of tegument proteins (VP16) and cellular factors 
(Oct1) prior to viral protein synthesis (126).  Six IE proteins (ICP0, ICP4, ICP22, ICP27, 
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ICP47, US1.5) are transcribed and translated two to four hours post infection (hpi) and 
several are involved in the induction of E gene expression (39).  Early gene transcription 
reaches its peak 4-8 hpi, and several E proteins replicate cellular function such as 
thymidine kinase (ICP36) and ribonucleotide reductase (ICP6).  DNA polymerase 
(UL30), DNA binding proteins (UL42, UL29), ORI binding protein (UL9), and 
helicase/primase complex (UL5, UL8, UL52 are the seven E proteins necessary and 
sufficient to carry out viral DNA replication (16).  The onset DNA replication leads to a 
reduction in E expression and the increase in expression of L genes encoding structural 
elements of the virion including glycoproteins.    
HSV DNA replication initiates after the linear viral genome is delivered to the 
nucleus and circularized.  DNA replication is thought to originate by a bidirectional theta 
mechanism, which is followed by rolling-circle replication resulting in head-to-tail 
concatemers of HSV genomes (16).  DNA concatemers are cleaved into individual 
genome segments during packaging into the preformed viral capsids.  The resulting 
nucleocapsid are enveloped by bud through the inner nuclear membrane (141), but 
competing theories for the HSV egress route have been presented.  
Historically, the double envelopment model has been the most widely accepted 
model. In this model capsid particle are enveloped by the inner nuclear membrane 
envelope, fuse with the outer nuclear membrane, and are released to the cytoplasm.  The 
capsids then association with tegument proteins and are re-enveloped by a cytoplasmic 
organelle, likely budding into the Trans Golgi Network for maturation and transported 
through the vesicular secretory pathway (23, 90).  A second model provides two 
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pathways for egress. First, a minority of capsids are enveloped by the inner nuclear 
membrane and travel intraluminally through the Rough ER (RER) to Golgi cisternae and 
package in to transport vesicles.  A second, primary route allows capsids direct passage 
from the nucleus to the cytoplasm through enlarged nuclear pores.  In the cytoplasm they 
can bud into cytoplasmic membranes (23, 78).  Whatever the mode of envelopment the 
end result is infectious HSV particles surrounded in a glycoprotein studded envelope.   
 
Viral entry strategies 
 Viral entry pathways are determined by interactions at the cell surface, and these 
critical interactions regulate the process viral genetic material uses to cross the cellular 
lipid bilayer.  Both non-enveloped and enveloped viruses must accomplish this task.  The 
non-enveloped viruses, lacking a lipid bilayer of their own, must transfer their genome 
across the cellular bilayer.  Enveloped viral genomes must transit both the viral and 
cellular bilayers (51).  The strategy used by each virus is dictated by the particular 
cellular conditions encountered at the site of penetration (137) 
 Non-enveloped viruses, lacking a lipid bilayer, use three main strategies to get 
their genetic material across the cellular membrane.  These strategies include transient 
lipid rearrangement, pore formation, and gross membrane disruption (98).  Non-
enveloped viral particles often require additional maturation steps, such as proteolysis 
and conformational alteration to be primed for cellular invasion. At the target cell each 
virus type is primed by a specific set of signals including receptor binding, low pH, 
protease cleavage, chaperone-assisted morphological changes, or divalent cation 
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chelation.  These triggers regulate capsid rearrangements known broadly as uncoating 
and help ensure the virus is in the proper state and location when activated for entry.  
Poliovirus, a member of the family Picornaviridae binds its cellular receptor CD155 and 
undergoes a conformational change exposing an amphipathic α-helix in the capsid 
protein (54, 89).  The α-helix is important for membrane penetration, pore formation, and 
ultimately genome release into the cytoplasm (98, 139).  Membrane pore formation, as 
described above for Picornaviridae, is also employed by the Parvoviridae and Reoviridae 
families, to facilitate genome release into the cytoplasm (1, 38, 62, 139).  Other non-
enveloped viruses such as adenovirus cause gross membrane disruption by lytic factor 
release facilitating genome entry into the cell (84). 
 Enveloped viruses depend on a mechanism capable of facilitating fusion between 
the viral and cellular membranes for their genetic material to gain entry.  Fusion between 
two bilayer membranes is a thermodynamically favorable process with a high kinetic 
barrier of 40-50 kcal/mol (71).  In enveloped viruses fusion proteins provide this 
mechanism and catalyze membrane fusion by overcoming the kinetic barrier using the 
free energy of conformational change.  The described viral fusion proteins contain 
several common characteristics. They are type I membrane proteins with a large 
ectodomain and two membrane-interacting regions, the C-terminal transmembrane 
anchor and a hydrophobic patch or fusion peptide. Also, they have a cytoplasmic tail and 
are trimeric in their post-fusion state (51, 145).  Viral fusion proteins are membrane 
bound with large ectodomains folded into a metastable pre-fusion state (51).  To 
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overcome the high energy barrier of membrane fusion a fusion protein undergoes 
conformational change and uses the energy released to drive fusion. 
 
Viral Fusion Proteins  
Three classes of viral fusion proteins, class I, class II and class III, are recognized 
based on their structure and mechanism of fusion, and are exemplified by influenza 
hemagglutinin (HA), tick-borne encephalitis virus (TBEV) E protein, and vesicular 
stomatitis virus (VSV) glycoprotein G respectively (Figure I-2) (95, 96, 111, 113, 120).  
Across these three classes of viral fusion proteins the route for catalyzing viral-cell fusion 
is believed to follow a similar process using the free energy liberated by conformational 
change to bring the viral and cellular membranes together (Figure I-3) (51).  Fusion 
proteins while diverse in sequence and structure all catalyze fusion using the same 
general process resulting a trimeric active state and post fusion structure.  Unique 
regulatory steps are present in each class, and even for each particular virus, providing 
control mechanisms for the fusion process (145).  
The surfaces of mature enveloped viral particles are covered in fusion proteins in a 
metastable fusion-competent state (Figure I-3A). A triggering event, specific to each 
fusion protein, leads to conversion into to a prehairpin intermediate homotrimer.  The 
prehairpin intermediate (Figure I-3B) forms a bridge between the viral membrane and 
target membranes connected though the C-terminal transmembrane anchor and the 
hydrophobic fusion peptide, respectively.  Next a series of conformational changes, or 
fold-back steps occur bring the two membrane inserted elements, the fusion peptide and 
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transmembrane anchor, together to create a trimer-of-hairpins (Figure I-3C-D) (25, 88).  
Through the fold-back process the membrane becomes distorted, progressing through 
hemifusion, small fusion pore formation, and finally the establishment of a stable large 
fusion pore (Figure I-3D) (51, 145).  Ultimately, formation of a stable six-helix bundle 
results in the fusion of the viral and cellular membranes and allows the transfer of the 
viral nucleocapsid into the cytoplasm to initiate replication (Figure I-3E).  
 
Class I Fusion Proteins 
Class I fusion proteins are trimeric pre-fusion and post-fusion with a characteristic 
long central α-helical coiled-coil, two heptad repeat regions, and N-terminal fusion 
peptide, which is initially concealed at the primer interface (51, 145).  Typically, the class 
I fusion protein is translated as a single polypeptide and cleaved into 2 proteins during 
post-translational processing or upon exposure to low pH in the endosome.  The fusion 
active portion contains the membrane anchor and remains attached to the viral 
membrane, while the second portion contains the receptor binding motif (145).   
Fusion between the viral and cellular membranes occurs generally as outlined 
above.  Briefly, the fusion protein is attached to the viral membrane by the 
transmembrane domain and to the cellular membrane by insertion of the fusion peptide. 
Conformational changes, initiated by a trigger (receptor binding or low pH), drive the 
fusion protein into a hairpin intermediate-state.  Then self-association of the heptad 
repeat regions support the formation of a stable six-helix bundle (6HB) in the  
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Figure I-2.  Class I, II, III fusion proteins; pre-fusion and post-fusion structures.  (A) 
Class I fusion protein Influenza virus HA2 crystal structures is shown.  (B)  Class II 
fusion protein TBEV E protein crystal structures.  (C) Class III fusion protein VSV G 
protein crystal structures.  (A-C) The pre-fusion states are on the left and post-fusion 
states on the right.  Functional domains are identified by color.  Adapted from White et al 
(145). 
Pre-fusion Post-fusion 
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Figure I-3.  Model of membrane fusion.  (A-E) The proposed sequence of events of 
membrane fusion mediated by viral fusion proteins.  Class I, II, III fusion proteins are 
thought to all follow this similar general series of steps to promote membrane fusion.  
Adapted from Harrison et al (51).   
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trimeric post-fusion form resulting in membrane fusion (145).   
Viruses containing class I fusion proteins include paramyxoviruses, retrovirues, 
filovirues, coronaviruses, and orthomyxoviruses (17, 42, 75, 100).  Influenza, a member 
of the Orthomyxoviridae family, contains the prototypical class I fusion protein, HA, 
which serves a model for the class.  A 220 kDa homotrimer with both receptor binding 
and fusion activity, HA's pre-fusion form was the first crystallized fusion protein, and HA 
remains one of the best studied viral fusion proteins (Figure I-2A) (145, 146).  HA 
consists of two disulfide-linked subunits, HA1 and HA2, derived by proteolytic cleavage 
of the HA0 precursor.  Cleavage of HA0 occurs in the trans-golgi network (TGN) and 
HA1 contains the receptor binding domain, while HA2 forms the central α-helical coiled-
coil region and contains the fusion active region with the heptad regions (HR1 and HR2) 
and the fusion peptide (51, 120).  The placement of the receptor binding domain and the 
fusion functional domain on separate proteins is typical of class I fusion proteins.   
Binding to the host ligand, sialic acid, through the HA1 subunit leads to 
endocytosis of the influenza virion (120).  Exposure to low pH following endocytosis 
induces irreversible conformational change in HA and release of the fusion peptide from 
its protected position allowing insertion into the target membrane.  The pre-hairpin 
intermediate form the fusion peptide is inserted into the target membrane and the 
transmembrane domain anchors HA to the viral envelope.  Now fusion protein spans the 
distance between the viral and target membranes (18, 145).  Next, HA2 folds back as the 
HR regions come together drawing the transmembrane domain and fusion peptide 
together with their associated viral and cellular membranes, respectively.  In the final 
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post-fusion form HA has folded back on itself to form a trimer of hairpins with a long 
central trimeric alpha-helical core packed at the C-terminal region by three shorter 
helices, also referred to as the 6 helix bundle (6HB) (Figure I-2A) (27).  Through 
conformation change this class I fusion protein has moved from a high energy metastable 
prefusion state to a more stable lower energy postfusion state and used the energy 
released to drive membrane fusion (51, 145). 
 
Class II Fusion Proteins  
 The viral glycoproteins E1 of Semliki forest virus (SFV) and E protein of Tick-
borne encephalitis virus (TBEV) are class II fusion proteins from Alphavirus and 
Flavivirus genera, respectively (Figure I-2B).  These are small, enveloped, positive-sense 
RNAviruses with a nucleocapsid and a lipid bilayer containing the viral transmembrane 
(TM) proteins. SFV E1 and TBEV E protein class II glycoproteins have distinct primary 
sequences with little homology, but they have significant secondary and tertiary structural 
homology (67).  Class II fusion proteins are thought to use a by a similar fold-back 
process as class I fusion proteins to bring the membranes together and facilitate fusion 
(145).  
Several key factors distinguish SFV E1 protein and TBEV E protein from class II 
fusion proteins from class I fusion proteins informing the class separation (77).  Class II 
fusion proteins are primarily composed of β-sheets with little α-helical content, have 
internal fusion loops at the tip of β-strands, are anti-parallel dimers lying flat on the 
virion surface in their pre-fusion form, and require a regulatory protein for proper folding 
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(67, 145).  Class II proteins associate with a regulatory protein during post-translational 
processing.  The regulatory protein may function to maintain the protein in its native 
metastable (67).  Cotranslation with a regulatory protein in class II fusion proteins 
differentiates them from class I fusion proteins that do not associate with a regulatory 
protein in this way.   
SFV fusion protein E1 is cotranslationally expressed with regulatory protein p62. 
After insertion into the endoplasmic reticulum the p62-E1 complex folds and continues 
transport along the secretory pathway toward the plasma membrane (67).  Late in the 
secretory pathway the p62 is cleaved by the cellular protease furin.  Furin cleavage of p62 
is a critical regulator step and produces an E2 transmembrane protein that remains stably 
associated with the p62/E1 dimer (68).  E2 contains the receptor binding domain and 
shields the internal fusion loops on E1 from premature exposure.  Each SFV virion buds 
from the plasma membrane covered with 80 trimers of E2/E1 heterodimers laying flat on 
the surface with T=4 icosahedral symmetry (46, 68, 114, 145).   
SFV and TBEV both undergo receptor-mediated endocytosis and require a low 
pH to trigger fusion. As the pH decreases SFV E2/E1 dimer undergoes a conformational 
change allowing exposure of the E1fusion loop and its insert into the target 
membrane(67).  This conformational change also results reorganization of E1 into 
trimmers, which are necessary for hairpin formation and fold-back leading to membrane 
fusion and a trimeric post-fusion structure. 
 
Class III Fusion Proteins 
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Class III fusion proteins were initially characterized through the surprising 
structural homology between vesicular stomatitis virus (VSV) glycoprotein G and HSV-1 
glycoprotein B, which contain no sequence homology and are a negative-stranded RNA 
virus and a DNA virus, respectively (56, 111).  VSV is a member of the Rhabdoviridae 
family, while HSV represents the large Herpesviridae family (39).  The VSV G structure 
has been resolved at neutral and low pH providing a picture of the pre-fusion and post-
fusion structures (Figure I-2C) (111, 113).  Analysis of these structures revealed 
characteristics found in both class I and class II fusion proteins, but an overall structural 
organization that was different than any previously described fusion protein (110).  The 
resolved structures showed that VSV G fusion proteins are trimeric pre-fusion and post-
fusion like a class I fusion protein and contain central α-helical structural elements.  
Class III fusion proteins also contain β-sheets and have internal fusion loops, both 
important secondary structural motifs of class II fusion proteins (111).  Importantly, class 
III fusion proteins appear to use conformational changes to power the formation of a 
hairpin structure that pull the viral and target membranes together in a similar manner as 
both class I and II fusion proteins indicating a common overall framework for achieving 
membrane fusion.    
 Comparison of HSV-1 gB structure and VSV G post-fusion structure reveals 
similar folds and, likely, a common evolutionary origin not evident in primary sequence 
comparison (56, 111, 127).  Other class III fusion proteins identified based on structural 
homology to VSV G include Epstein-Barr virus (EBV) gB and baculovirus gp64 (9, 66).  
In comparison to VSV G where both pre-fusion and post-fusion structures have been 
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resolved, the gBs and gp64 are presumed to be post-fusion conformations.  They are 
homotrimeric with a long central coiled-coil like class I, and internal bipartite fusion 
loops similar to the single fusion loop in a class II fusion protein (117).   
VSV is a small, negative sense, enveloped RNA virus with a bullet shaped 
morphology resembling other Rhabdoviruses, such as rabies virus (39).  VSV has been 
widely used as a model system due to its broad cell tropism, one of the broadest of any 
enveloped virus, and the ability to grow large quantities of virus at high titers (39, 74).  
Many aspects of this bullet shaped rhabdovirus, from entry and fusion to replication and 
assembly, are well characterized (39).  VSV is a virus of economic concern for the 
livestock industry causing significant morbidity, but its extensive study is largely due to 
its tractability in experimental systems.  
The VSV receptor remains unidentified, but may aspects of its entry have been 
well-characterized biochemically and through structural analysis.  The VSV envelope is 
covered with a single protein, the 495 amino acid, type I transmembrane protein spikes 
know as glycoprotein (G), which functions in both attachment and entry (30).  Following 
receptor binding VSV is taken into endocytic pathway of target cells by clathrin-mediated 
endocytosis (65).  Exposure to acidic pH of the endsome induces significant 
conformational changes in VSV G resulting in fusion and ultimately nucleocapsid release 
(111, 113). 
Earlier biochemical analysis identified three conformational states in G; 
prefusion, activated hydrophobic, and post-fusion (44, 110).  The post-fusion state was 
recognized as antigenically distinct from the first two, and a shift toward the post-fusion 
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state observed upon exposure to low pH.  Interestingly, these antigenic changes observed 
in G at low pH were reversible upon return to neutral pH, a property not observed in class 
I and class II fusion proteins (43, 112).   
As described above, the pre-fusion and post-fusion VSV G ectodomain structures 
have been resolved (Figure I-2C), and were identified along with HSV-1 gB to represent 
a new class of fusion proteins, class III (56, 111, 113).  To mediate viral entry into cells 
VSV G and baculovirus gp64 are sufficient, and serve the attachment, receptor binding, 
and fusion functions without the need for other viral proteins (14, 110, 150).  HSV gB is 
not sufficient to mediate fusion on its own even through its structure resembles post-
fusion VSV G.  HSV requires three other proteins, gD and gH/gL heterodimer, along 
with gB for successful entry and fusion. (105). 
 
Herpesvirus entry 
 Herpesviruses encompass a large family of enveloped viruses with a conserved 
fusion mechanism.  Nine human herpesviruses have been characterized, and in excess of 
130 herpesviruses have been identified in all species (39).  They are dispersed across the 
three subfamilies; alpha-, beta-, and gammaherpesviruses.  The alphaviruses are HSV 
types 1 and type 2 (HSV-1 and HSV-2) and varicella-zoster virus (VZV).  The 
betaherpesviruses include cytomegalovirus (CMV) and human herpesviruses 6A, 6B, and 
7 (HHV-6A, HHV-6B and HHV-7).  The two gammaherpesviruses are Epstein-Barr 
virus (EBV) and Kaposi’ sarcoma herpesvirus (KSHV) also known as human herpesvirus 
8 (HHV-8) (55).  Across all herpesvirses entry and fusion is mediated by homologs of 
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three highly conserved proteins, gB and gH/gL (Figure I-4).  In addition to these 
conserved entry proteins a receptor binding protein is necessary, and a wide variety are 
used throughout the Herpesviridae (Figure I-4).  HSV and its entry requirements are 
further evaluated below. 
 HSV entry has historically been reported to occur at the plasma membrane by 
direct fusion as seen in Vero cells (Figure I-5A) (147).  Entry through the endosomal 
pathway has also been reported, under both neutral and acidic conditions (99).  
Interestingly, the mode of entry varies by cell type, but in all cases gD and the core fusion 
machinery gH/L and gB are necessary.  Entry through the endocytic pathway seems to 
predominate in HeLa, CHO-K1 expressing gD-receptor nectin-1, and primary human 
keratinocytes, and requires acidification for successful fusion (Figure I-5B) (99).  B78H1 
mouse melanoma cells expressing gD receptor nectin-1 are reported to use the endocytic 
pathway for entry but without a requirement for low pH as seen in the cell types above 
(Figure I-5C) (92).  HSV’s ability to infect a wide variety of cell types may be a function 
of the multiple receptors it can bind to initiate successful entry, and this variety may 
contribute to the varied entry pathways. 
HSV employs four glycoproteins proteins in a complex entry mechanism, and 
each is required for successful entry.  These four proteins are gD, gH, gL, and gB (Figure 
I-6).  Glycoprotein D (gD) is the receptor binding protein for HSV and has three known 
cellular receptors, which are herpes virus entry mediator (HVEM), nectin-1, and 3-OS- 
modified heparan sulfate moieties (121).  The core herpes fusion machinery includes 
gH/gL heterodimer and gB, which are highly conserved throughout all herpesviruses.   
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Figure I-4. Entry proteins of human herpesviruses.  All eight human herpesviruses 
require gB and gH/L for entry.  Recepter binding is performed by gD in the 
alphaherpesviruses except for VZV, which uses gE.  Betaherpeseviruses and 
gammaherpesvirues bind receptor(s) using gB, gH/gL, or an accessory protein.  Adapted 
from Heldwein and Krummenacher (55). 
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Figure I-5. Routes of HSV entry.  (A) Entry into Vero cells occurs at the plasma 
membrane and is pH-independent.  (B) HSV enters CHO-nectin-1 expressing cells by 
pH-dependent endocytosis, but cannot enter CHO cells without nectin-1.  (C) Like CHO 
cells, B78 cells require a transformation with a gD receptor. Here B78 cells are 
transfected with nectin-1. Entry into these cells is by pH-independent endocytosis.  
Adapted from Milne et al (92). 
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Importantly, the four glycoproteins (gD, gH/gL, gB) and a receptor (HVEM or nectin-1) 
are necessary and sufficient to complete cell fusion (4, 138).  
 
gC 
Glycoprotein C (gC) is a nonessential glycoprotein that plays a role to aid entry 
by binding heparin sulfate proteoglycans (HSPG) fostering virus-cell attachment (55).  
Initial viral attachment occurs through the non-essential glycoprotein gC and 
independently through gB by binding heparan sulfate proteoglycans (HSPG) (12, 123).  
Cells deficient in proteoglycan synthesis have a significant reduction in viral infection, 
but remain permissive to HSV indicating HSPG is not essential for infection (10).  
Additionally, gC mutant HSV virions remain infectious, albeit at a lower level, while gB 
null virions are non-infectious (21, 57).  These data support that gC and HSPG binding 
are nonessential for HSV entry, while gB is essential.  gB, the focus of this thesis, will be 
discussed further in later sections. 
 
gD 
 HSV-1 gD, the receptor binding protein, binds one of three cellular ligands, and 
plays an important role in virus tropism.  gD is a 369 amino acid type 1 membrane 
protein with a immunoglobulin V-like fold at its core as seen by its crystal structure. N- 
and C- terminal extension wrap around the core, and gD is thought to form a homodimer 
on the virion surface (Figure I-6).  Understanding of gD binding to its main cellular 
ligands, HVEM or nectin-1, has been significantly advanced by successful crystallization 
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of gD in complex with each ligand (24, 31).  Glycoprotein D binding with its receptors is 
essential for viral entry, and data supports that this binding transmits a single downstream 
that allows gH/gL and gB to complete fusion with the cell membrane.  In vivo both gD 
receptors, HVEM and nectin-1, seem to be relevant for continued infection.  Patient 
isolated virus samples retain the ability to use either receptor no matter the location of the 
lesion from which virus was collected (70).   
HVEM is a tumor necrosis factor-like receptor found in the greatest abundance on 
T cells (Figure I-6).  HVEM is widely expressed, but is found at high levels in the spleen, 
thymus, lungs, B cells, monocytes, and T cells (72).  For HSV entry HVEM is a 
functional receptor in in activated T cells, oral epithelial cells, and corneal fibroblasts (61, 
97, 134).  HVEM has several natural ligands providing stimulatory signals (LIGHT, 
lymphotoxin alpha) and inhibitory signals (BTLA and CD160) that together modulate the 
immune response (47, 52, 87, 116).  Interestingly, HSV does not replicate successfully in 
T cells (128).  This provides the intriguing possibility that gD-HVEM interactions may 
modulate the host immune response, possibly aiding virus replication and latency.  
Nectin-1, a cell adhesion molecule located at adhesion junctions, is found at sites 
distinct from HVEM, and is abundant on epithelial cells, fibroblasts, and on neurons (94, 
97, 130).  Nectin-1 and its family members (nectin-2, -3, -4) contain three Ig-like 
domains, a transmembrane domain, and cytoplasmic tail (Figure I-6).  Nectin-1 acts as a 
receptor for HSV-1 and HSV-2, and is the primary receptor on epithelial cells and 
neurons (61, 119).  Nectin-1 is also a receptor for pseudorabies virus (PRV) and bovine 
herpesvirus type-1 (BHV-1), both alphaviruses like HSV (45).   
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Figure I-6.  Proteins required for HSV entry.  Four essential glycoproteins (gB, gD, and 
gH/gL) are required for HSV entry.  gD interacts with one of the key cellular receptors, 
HVEM or nectin-1.  The crystal structures of each glycoprotein and receptor are depicted. 
Adapted from Eisenberg et al (36). 
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 The third gD receptor, heparan sulfate proteoglycans (HSPG) are carbohydrate 
chains covalently linked to proteins.  HSPGs are secreted into the extracellular matrix or 
are cell associate.  They are expressed ubiquitously on mammalian cells and interact with 
growth factors, cytokines, chemokine, and morphogens.  HSPGs have a wide variety of 
important functions in development, morphogenesis, cell adhesion, and hemostasis (37).  
HSPGs are made of a core protein and one or more linear polysaccharide, or 
glycosaminoglycan (GAG), chain covalently attached in the ER.  The HS undergo a 
series of processing reactions in the Golgi to deacetylate, sulphonate, and otherwise 
modify the chains for its specific role and location (13).   
  3-O-sulfated heparan sulfate (3-OS-HS) only functions as a receptor for HSV-1.  
3-OS-HS binds gD in several cell lines (HeLa, Vero), and is an important receptor for 
primary corneal fibroblast infection (118) (101, 133). 
   
gH/gL 
  The gH/gL heterodimer is a part of the core herpesvirus fusion machinery and is 
highly conserved.  HSV-1 gH is a 838 amino acid with a large ectodomain and membrane 
anchor, while gL is 224 amino acids protein without a transmembrane segment (26). The 
heterodimer requires formation of the 1:1 gH/gL complex where gL functions as a 
chaperone essential for proper processing and trafficking of gH (103).  gH/gL is a major 
target for HSV neutralizing antibodies supporting its importance in the entry process 
(103).  Several studies have suggested gH/gL may have fusogenic properties due to 
identification of fusion activity of gH derived synthetic peptides and the predicted 
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presence of heptad repeat regions in gH (40, 41).  Recently, the gH/gL crystal structure 
was solved for HSV-2 as well as EBV and a fragment of PRV gH, and had no structural 
homology to a known fusion protein. Additionally, the predicted heptad repeat region 
formed helices excluding a role in fusion (Chowndary 2010)(6, 86).  An interaction 
necessary for cell-cell fusion was identified between gH/gL and gB using bimolecular 
complementation (4, 5). Additionally, gH/gL and gB cofloatation with liposomes was 
observed at low pH (22). These data support the idea that interaction between gH/gL is 
necessary for fusion.  
 
HSV glycoprotein B 
 Glycoprotein B is the most highly conserved herpesvirus entry proteins protein.  
gB is 904 amino acid protein produced from a 934 amino acid polypeptide with the 30 
amino acid signal sequence cleaved during the maturation process (Figure I-7).  gB 
contains a 697 amino acid ectodomain, a 68 amino acid membrane proximal and 
transmembrane domain, and a 109 amino acid cytoplasmic domain.  The membrane 
proximal and transmembrane region spans amino acids 731-794, and contains three 
hydrophobic domains.  Residues 731-773 contain the two hydrophobic domains and are 
named the membrane proximal region (MPR).  The third hydrophobic region represents 
the transmembrane domain anchoring gB to the viral membrane (108). 
gB is structurally homologous to VSV G and baculovirus gp64, but does not share 
sequence homology with these fusion proteins (56, 66, 111).  This structural homology 
identified gB as a class III fusion protein.  gB is trimeric with two fusion loops per 
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protomer, β-sheets, PH domain, and a long central α-helices (56).  gB was suspected to 
have fusion activity before the structure was resolved due several pieces of data.  In the 
early studies of HSV a syncytial phenotype was observed, and the genotype was localized 
to point and truncation mutants in gB (20, 132).  Mutational analysis of the putative 
fusion loop region through point mutants and linker insertions identified mutations that 
altered gB’s ability to mediate cell-cell fusion (49, 50, 82).  Point mutations in the 
putative gB fusion loops (W174, Y179, H263, R264) decreased or completely abrogated 
the ability of soluble gB (730t) to associate with liposomes (49).  These data further 
support a role for gB in fusion and entry.   
Detailed analysis of the gB crystal structure identified five distinct structural 
domains in the 85Åx80Åx160Å elongated trimer, which resembles the size and shape of 
spikes observed on HSV-1 virions by electron microcopy (56, 125).  The crystallized 
construct contained HSV-1 residues 133 to 730, and was produced in a baculovirus 
expression system as a soluble protein (Figure I-7).  The soluble protein was then purified 
by immunoaffinity chromatography and named gB730t.  The resulting trimeric structure 
contains three protomers, each with five domains.  Domain I (residue 153 to 363) forms 
the base and contains a PH-like domain and a β-sandwich made of 2 β-sheets.  PH 
domains facilitate phosphoinosital binding and protein-protein interactions, which may be 
important for gB function (76).  Importantly, the two proposed fusion loops occupy the 
folds in two adjacent β-strands of each protomer and project toward the membrane (56).  
The specific properties of gB fusion loops will be discussed in a later section.  
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Figure I-7.   Structure of HSV gB.  (A) domain architecture of gB.  Domains are 
highlighted in different colors with their first residue position shown.  (B) Ribbon 
diagram of a single gB protomer with domains labeled and colored identically to (A).  (C) 
Surface representation of gB trimer with domains of one protomer colored according to 
(A).  Adapted from Heldwein et al (56).	  	   	  
	   	  	  
membrane	   
proximal	   
region TM 
cytoplasmic 
domain 
A 
B C 
	  
	  
	  
31	  
Domain II is formed by two discontinuous segments and forms another PH-like 
domain.  Domain III is made of 3 discontinuous segments and contains a long α-helix 
that with the adjacent protomers forms the central coiled-coil of gB with many essential 
trimer contacts (56).  Domain III bears a strong similarity to the central coil-coiled in 
class I fusion proteins.    
Domain IV, the crown, is also formed by two discontinuous segments that are 
linked by a disulfide bond forming a globular structure at the top of the structure (56).  
No structural relatives have been described for this region. Notably, several neutralizing 
monoclonal antibodies have been mapped to similar surface epitopes suggesting domain 
IV is exposed on the virion surface (56, 58).   
Domain V is a long extension (residues 670 to 725) stretching from the top to the 
bottom of gB.  This long extension fits in the groove between the other two protomers, 
but has no contact with any other portion of its own protomer.  These interactions may 
help stabilize the trimer.  The crystallized structure ends at amino acid 725, leaving the 
remaining C-terminal portion of the ectodomain, the transmembrane domain, and the 
cytoplasmic domain unresolved.  The missing ectodomain contains the hydrophobic 
MPR (residues 731-773) that was removed from the soluble gB construct used for 
crystallization due to its hydrophobic character (56).  Chapter II will focus on 
investigating what role the MPR plays in gB fusion.  
The available evidence suggests that the HSV gB structure is the post-fusion form 
due to similarities with the extended post-fusion VSV G.  In the future examination of a 
second, presumably pre-fusion gB structure would provide evidence that the current 
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structure is the post-fusion form (111).  Several studies report conformational changes in 
gB when exposed to low pH (22, 34).  Analysis of a low pH structure of gB detected a 
major shift in the position of fusion loop 2, but no global pH-dependent changes in the 
fusion protein were noted.  This fusion loop 2 shift is hypothesized to be important for 
endocytic entry of HSV, but the observed changes are not the global rearrangements one 
would anticipate for the pre-fusion form (124).  Antigenic changes detected in soluble gB 
at low pH caused a change in the oligomeric structure toward the monomeric state.  Upon 
return to a neutral pH these changes were reversible (34).  Reversibility from pre-fusion 
to post-fusion is a key characteristic of VSV G and class III fusion proteins, and it 
appears gB has a reversible component to its conformational changes due to pH.  
Significantly, the conformational changes detected in gB antigenically and by crystal 
structure do not appear as profound as those observed for VSV G (110, 111).  Using 
structural data to develop a model of the gB pre-fusion structure and its transition to post-
fusion provides detailed analysis of fusion protein.  Until a pre-fusion structure is solved 
a variety of techniques including targeted mutations, antigenic analysis, and lipid binding 
assays are used to continue to dissect gB’s role in HSV entry and fusion.    
Using the presumed post-fusion structure of gB, and the homologous VSV G 
structural data, targeted mutagenesis was used to evaluate the proposed HSV fusion 
loops. The two HSV gB fusion loops (FL), aa 173 to 179 and 258 to 265, in domain I 
were mutated at structurally significant residues.  Mutation of gB FL residues W174, 
Y179, and A261 resulted in loss cell-cell of fusion, and mutations at W174, Y179, H263, 
R264 led to impairment or loss of liposome association (49, 50).   The availability of the 
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crystal structure allowed characterization of regions important for viral fusion and 
infection led to a functional map of the gB structure as described below. 
 
gB Functional Regions 
 Mapping functional regions (FRs) using neutralizing antibodies is a common way 
to identify important regions. Numerous studies have used monoclonal antibodies to 
identify FRs of gB (3, 49, 50, 82, 104).  Careful characterization of a 67 monoclonal 
antibody panel to HSV gB identified eleven neutralizing antibodies and facilitated the 
identification of functional regions.  An overlapping peptide panel was used to identify 
epitopes and then the epitopes were mapped onto the HSV-1 gB ectodomain structure 
identifying four FRs (11).  The four FRs are spread over the entire ectodomain with some 
spanning multiple structural domains (Figure I-8).   
FR1 includes the domains I and V, contains the putative fusion loops, and is 
recognized by several neutralizing monoclonal antibodies.  Monoclonal antibody SS55 
was mapped to domain I, and is a potent neutralizer.  Another FR1 virus neutralizing 
antibody, SS144, mapped to the long α-helix of domain V near the carboxy-terminus of 
the gB crystal structure (11).  Interestingly, both SS55 and SS144 block soluble gB(730t) 
from associating with liposomes in a coflotation assay (49).  The presence of the putative 
fusion loops, multiple neutralizing antibodies, and the disruption of liposome association 
strongly suggests FR1 is important for virus entry and fusion.  
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Figure I-8.  gB functional regions.  HSV gB FRs are defined by the epitopes 
of neutralizing MAbs: SS55/SS106/SS144 (FR1, blue and red, fusion domain), 
C226/H1838/H1781 (FR2, green, gH/gL interaction domain), SS10/SS67-69 (FR3, 
orange, receptor-binding domain). The epitope of MAb H1817 (FR4, dotted circle) maps 
to the unresolved N-terminus. (A) Ribbon diagram of gB protomer with functional 
regions outlined in black.  Representative monoclonal antibodies used to define these 
regions are listed.  (B) Space filling model of gB trimer with functional regions labeled. 
The fusion loops are indicated at the bottom of the structure. Adapted from Hannah et al 
and Eisenberg et al (36, 49). 
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FR2 is on the outer surface of domain II, and represented by C226 neutralizing 
antibody.  C226 type-common recognizing both gB1 and gB2, and identifies domain II as 
critical to HSV entry.  FR3 encompasses residues located in domain III and domain IV 
includes the epitope of neutralizing antibody SS10.  The SS10 epitope includes residues 
640-670, which are highly conserved among herpesviruses (56).  This epitope is in 
domain IV at the top or crown of the structure opposite the viral membrane in the 
presumed post-fusion structure.  Interestingly, SS10 blocks soluble gB’s ability to bind to 
cells, but does not interfere with gB liposome association (11, 49).  FR4 is formed by a 
region of the gB N-terminus that was not solved in the crystal structure, and contains the 
gB heparin sulfate binding region (11, 12).  
 
Membrane Proximal Region 
The membrane proximal region (MPR) is a portion of the ectodomain adjacent to 
the transmembrane domain of viral fusion proteins.  The MPRs of viral fusion proteins all 
show an abundance of hydrophobic and aromatic residues (W, Y, F), and thus have high 
hydrophobic character.  In contrast, the number and spacing of these aromatic residues 
vary with each fusion protein (7) (29).  Mutations in the MPR of multiple fusion proteins 
including HIV1 gp41 (115), HPIV 2 F protein (136), SV5 F protein (151), VSV 
glycoprotein G (63, 64), baculovirus gp64 (79), and HSV gB (82) indicate they play 
important roles in the regulation of membrane fusion.  It is thought that the aromatic and 
hydrophobic properties of MPRs indicate a function in bridging the gap at the lipid 
interface between aqueous and hydrophobic environments (7, 69).   
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The seventeen residue membrane proximal region of HIV-1 gp41 is known as the 
membrane proximal external region (MPER), and is involved in virion assembly and 
infection (115).  The structure of this tryptophan rich region of gp41 was recently solved.  
The MPER crystal structure places three aromatic side chains per monomer facing 
towards the membrane on a non-classical coiled-coil structure (19).  These aromatic 
residues are positioned for membrane insertion and data supports the notion that gp41 
MPER structural motif aids the generation of viral membrane curvature and ultimately 
fusion (19).  The deletion of seventeen residues of the MPER or mutation of five 
conserved tryptophan residues to alanine abolished cell-cell fusion.  Single tryptophan 
mutations resulted in decreased infectivity (115).  Interestingly, the epitope for a broadly 
neutralizing antibody, 2F5, is located in the MPER highlighting the importance of this 
structure in infection (60).  
The twelve residue membrane-proximal region of the human parainfluenza virus 
type 2 (HPIV2) F protein, is necessary for fusion activity but not surface expression 
(136).  Importantly, three residues (N475, F476, and F477) were identified to be critical 
for cell fusion activity, and when singly mutated to alanine F protein was unable to 
mediate hemifusion.  The inability of the F protein MPR mutants to initiate hemifusion 
indicates the MPR is involved in lipid mixing (136). 
The SFV class II fusion protein E1 has a MPR that is thought to play a role in the 
conformational change during fusion. Although structural data is unavailable, site-
directed antigenic analysis revealed that at neutral pH epitopes on the MPR are 
unavailable.  Upon low pH triggering and E2/E1 heterodimer dissociation the MPR 
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became accessible to antibodies (81).  In the post-fusion conformation the MPR again 
became inaccessible and appears to pack on the trimer core aiding hairpin formation.  
After further conformational change during hairpin formation the MPR epitopes again 
became inaccessible (80, 81).  Interestingly, neither E1 protein MPRs conserved length 
nor any specific residue was required for membrane fusion, but large insertions or 
deletions do decrease fusion (80).  
The 42 amino acid VSV glycoprotein G MPR is absent from the solved crystal 
structures of VSV G, but significant mutational analysis has been performed on the 
region to inform its function (7). A significant degree of sequence homology exists 
between the C-terminal regions of the vesciculoviruses suggesting a functional role for 
this region.  The MPR is hypothesized to stretch from the crown to the TMD in the VSV 
G post-fusion structure (111).  One hypothesized role for the MPR is as a flexible tether 
to position VSV G properly between the viral and cellular membrane (110).  
Additionally, there are mutation of conserved aromatic residues (W and F) singly or 
together had little effect on cell-cell fusion.  This is in contrast to tryptophan residues that 
have been shown to be important in HIV-1 gp41 MPR fusion activity (63, 115).  Further 
mutational analysis identified significant reduction in cell-cell fusion and infectivity 
when 13 residues (N449 to W461) of the MPR were deleted.  Insertions also decreased 
fusion activity and infectivity (63).  These studies strongly support a role for the VSV G 
in membrane fusion, but its specific function remains elusive.   
Although the transmembrane domain and MPR are not included in the resolved 
structures of pre- and post-fusion VSV glycoprotein G the fusion loops are mapped and 
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the structure suggests they are in close proximity to the transmembrane region (111, 113).  
One interpretation of these observations is that the MPRs simply functions as a flexible 
tether from the transmembrane domain and allows the proper alignment of the fusion 
protein with the membrane required for fusion to proceed (110).  Alternatively, as 
suggested above the MPR may play a role at the lipid interface to assist destabilizing of 
membranes and promote lipid mixing (64, 129).  Others have hypothesized a role for the 
MPR to regulate fusion more directly, for example in HSV-1 gB the fusion loops may be 
masked by the hydrophobic MPR preventing premature exposure to membrane (50).   
As outlined above the MPRs of both class I and class II fusion proteins play a role 
in cell-cell fusion.  The lack of structural data for most MPRs limits our understanding of 
the specific role the MPR plays in fusion.  The MPR of class III VSV G is also important 
for successful viral membrane fusion, but specific residues, such as tryptophan like gp41 
have not been identified as critical to function.  Analysis of HSV gB MPR, also excluded 
from the crystal structure, may provide insight into gB specifically and class III fusion 
proteins generally.   
Structural data is not available for HSV gB MPR since the crystallized construct 
was truncated just prior to the MPR at residue 730 (56).  Exclusion of the MPR (731-773) 
was due to the negative effect a highly hydrophobic region like the MPR can have on the 
ability to crystal the protein (Figure I-9).  Although there is no available structure of a 
class III fusion protein MPR several studies have assessed its functional importance in 
herpesvirus gB.  While mutations in the HIV1 gp41 and VSV G MPRs do not disrupt 
their expression and folding, the herpesvirus gB MPR appears sensitive to mutation 
	  
	  
	  
39	  
resulting in defective protein folding and decreased cell surface expression (63, 82, 108, 
115, 142, 149).  Misfolding and low surface expression of mutants made it difficult to 
assess the gB MPRs functional role. However, the few HSV gB MPR mutants that are 
expressed on the cell surface are impaired in cell-cell fusion or virus entry (82, 142).  
Generally, it is thought that in the pre-fusion form a fusion protein must mask its fusion 
loops to prevent premature virus activation or interactions that would result in decreased 
virus infectivity.  In the post-fusion structure of HSV gB the fusion loops are not masked 
by another portion of the solved structure, which does not include the MPR (56).  In 
contrast the fusion peptides of class I are protected within the trimer interface and fusion 
loops of class II proteins are masked at the dimer interface (96, 145).  Hannah et al. (50) 
proposed that due to its hydrophobic nature the HSV1 gB MPR could mask the 
hydrophobic fusion loops in the pre-fusion state.  Interestingly, purified EBV gB 
truncated to remove the C-terminus including the MPR self-associated forming rosettes 
visible on electron microscopy (8).  This association, presumably through the 
hydrophobic fusion loops, supports the speculation that masking of these hydrophobic 
fusion loops may prevent self-association or premature inactivation of fusion proteins. 
 
Aims of present work 
 Each protomer of the gB trimer includes two fusion loops (a.a. 173-179 
and 258-265) and a MPR (a.a. 731-773) (20, 49, 50, 56, 102, 108).  The goal of my 
dissertation has been to further define the role the gB fusion loops and MPR play in HSV 
membrane fusion and its regulation.  The construct used for gB crystallization lacked 
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Figure I-9.  gB membrane proximal region.  (A) The amino acid sequence of the HSV 
gB membrane proximal region (MPR).  (B) Kyte-Doolittle hydropathy plot of gB 
sequence.  The signal sequence in demarcated by a box at the amino terminus of gB.  The 
putative MPR and TM domains are marked by black box. A positive peak greater then 
1.6 indicates a high hydrophobicity score.  (C) An expanded view of MPR/TM boxed 
region in (B) showing a high hydrophobicity score.  Web based Kyte-Doolittle calculator 
web.expasy.org/protscale/ and Kyte and Doolittle (73). 
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the MPR and the putative fusion loops were exposed with no mechanism to prevent 
premature membrane interactions (56).   
The forty-three amino acid MPR has a highly hydrophobic character and this 
region was excluded from the crystalized gB construct due to its potential to decrease the 
probability of successful crystal formation.  In the second chapter of this dissertation 
various gB MPR deletion and truncation mutants were constructed.  The deletion 
mutants, expressed in mammalian cells in a full-length gB background, were not 
efficiently expressed on the cell surface.  Next recombinant baculovirus expressed C-
terminal gB MPR truncations were assayed for their membrane binding ability.  I found 
that despite the presence of fusion loops, purified soluble gB containing as few as the first 
nine MPR residues (gB739t) was deficient in the ability to bind liposomes.  In 
comparison, gB(730t) lacking the entire MPR has been shown to bind liposomes (49).  
Remarkably, mutation of two aromatic residues to alanine in the short nine amino acid 
MPR was sufficient to restore the liposome binding ability of the soluble gB protein 
(117).  Together, these data suggest an important interaction within FR1 involving the 
MPR that regulates liposome binding.   
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CHAPTER 2 
 
The membrane proximal region (MPR) of herpes simplex virus gB regulates association 
of the fusion loops with lipid membranes 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter appeared as the published article “The membrane-proximal region (MPR) of 
Herpes Simplex Virus gB regulates association of the fusion loops with lipid membranes” 
by S. S. Shelly, T. M. Cairns, J. C. Whitbeck, H. Lou, C. Krummenacher, G. H. Cohen, 
and R. J. Eisenberg. MBio. 2012 Nov 20; 3(6). 
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ABSTRACT 
Glycoprotein B (gB), gD, and gH/gL constitute the fusion machinery of herpes simplex 
virus (HSV).  Prior studies indicated that fusion occurs in a stepwise fashion whereby the 
gD/receptor complex activates the entire process, while gH/gL regulates the fusion 
reaction carried out by gB.  Trimeric gB is a class III fusion protein.  Its ectodomain of 
773 amino acids contains a membrane proximal region (MPR, residues 731-773) and two 
fusion loops (FL) per protomer.  We hypothesized that the highly hydrophobic  MPR 
interacts with the FLs, thereby masking them on virions until fusion begins.  To test this 
hypothesis, we made a series of deletion, truncation, and point mutants of the gB MPR.  
Although the full-length deletion mutants were expressed in transfected cells, they were 
not transported to the cell surface, suggesting that removal of even small stretches of the 
MPR was highly detrimental to gB folding.  To circumvent this limitation, we used a 
baculovirus expression system to generate four soluble proteins, each lacking the 
transmembrane region and cytoplasmic tail.  All retained the FLs as well as decreasing 
portions of the MPR [gB(773t), gB(759t), gB(749t), gB(739t)].  Despite the presence of 
the FLs, all were compromised in their ability to bind liposomes as compared to the 
control, gB(730t), which lacks the MPR.  We conclude that residues 731-739 are 
sufficient to mask the FLs, thereby preventing liposome association.  Importantly, 
mutation of two aromatic residues (F732, F738) to alanine restored the ability of 
gB(739t) to bind liposomes.  Our data suggest that the MPR is important for modulating 
the association of gB FLs with target membranes. 
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INTRODUCTION 
Herpes simplex virus (HSV) has four envelope glycoproteins that are essential for 
virus entry into cells: gD, gH, gL, and gB. All herpesviruses use a combination of gB and 
the heterodimer gH/gL to carry out fusion (9, 14, 16, 30, 41, 42); these three proteins are 
considered the core fusion machinery.  For HSV, an additional protein, gD, is part of this 
machinery.  Our current model of HSV fusion starts with the binding of gD to one of its 
receptors, likely transmitting a signal to gH/gL, which in turn acts upon gB to trigger 
fusion (3).  HSV-1 gB is a 904 amino acid type I membrane glycoprotein whose crystal 
structure identifies it as a class III fusion protein (23).  Although there is no primary 
sequence conservation, HSV-1 gB shares a high degree of structural homology with other 
class III fusion proteins including vesicular stomatitis virus (VSV) G (46), baculovirus 
gp64 (26), and Epstein-Barr virus (EBV) gB (5).  According to ultrastructural data (5, 23, 
26, 46), these presumed post-fusion conformations show that all are homotrimers with a 
long central coiled coil structure reminiscent of class I fusion proteins.  Yet, all have 
internal bipartite fusion loops (FLs) which are similar to the single internal FL of class II 
fusion proteins (14, 28, 31, 55).  Single point mutations within either of the gB fusion 
loops caused loss of cell-cell fusion and failure of soluble gB to associate with 
membranes (20, 21). 
For VSV G, ultrastructural data are available for both pre- and post-fusion forms 
(46, 47) and indicate that the FLs are situated near the transmembrane region and are 
close to the viral membrane in both forms.  For the fusion loops to start and end in this 
position, it is presumed that an intermediate step occurs where the fusion loops reposition 
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to the top of gB to interact with the cellular membrane.  Then, as gB changes 
conformation to its post-fusion form, it pulls the viral and cellular membranes close 
together to facilitate lipid mixing.  The prevailing concept is that these hydrophobic loops 
would be masked on the virus surface prior to fusion activation to avoid premature or 
otherwise unwanted interactions that may be detrimental to virus infectivity. 
The form of HSV gB used for crystallization ended at amino acid 730, leaving the 
fusion loop region exposed (23).  Residues downstream of amino acid 730 were initially 
excluded for crystallization trials due to their elevated hydrophobicity, which could 
impede crystal formation.  These downstream residues (731-773) constitute the gB 
membrane proximal region (MPR) (10, 23, 40, 43).  The structure of the MPR remains 
unknown for any of the class III fusion proteins but it seems likely to be in close 
proximity to the FLs (Figure 2-1A).   
MPRs provide essential functions in different types of fusion proteins.  Mutations 
within the MPRs of the fusion proteins for HIV (50), paramyxoviruses (57, 64), VSV 
(24), and baculovirus (34) abolish fusion but do not affect cell surface protein expression.  
MPRs are characteristically rich in aromatic residues (W, Y, F) (56) that have been 
proposed to bridge the gap between the aqueous and hydrophobic environments present 
at the lipid interface (29).  These aromatic residues could also act in concert 
(synergistically) with fusion peptides/loops to destabilize membranes and promote lipid 
mixing (25, 56).  Indeed, aromatic residues are also vital in FL function; it is presumed 
that their side chains, along with their carbon backbones, are inserted into the target 
membrane (37, 44, 46).  Interestingly, the MPR of baculovirus gp64 does not contain any 
	  
	  
	  
68	  
aromatic residues, but its bulky leucine residues appear critical for cell-cell fusion (34).  
MPRs might also act as flexible tethers to help fusion proteins become properly 
positioned between two lipid bilayers, as described for VSV G (45).   
Several studies of gB from different herpesviruses highlight the functional 
importance of its MPR.  Most gB MPR mutants are defective in protein folding and cell 
surface expression (35, 43, 58, 62), making it difficult to assess its functional role.  
However, the few HSV gB MPR mutants that are expressed on the cell surface are 
impaired in cell-cell fusion or virus entry (35, 58).   
Previously, we suggested that the MPR could mask the hydrophobic FLs in the 
pre-fusion state (21) in a way that would be analogous to how the FLs of class II fusion 
proteins are masked at the dimer interface (18, 48, 61).  Our goal here was to carry out a 
systematic analysis of the MPR.  We first made a series of MPR deletion mutants in this 
region in full-length gB and expressed each mutant in mammalian cells.  Unfortunately, 
none of these mutants were efficiently transported to the cell surface, a defect previously 
reported for other gB MPR deletions (43).  We next constructed recombinant 
baculoviruses to express C-terminal gB truncation mutants, containing various lengths of 
the MPR.  Despite the presence of the fusion loops, all of the proteins containing portions 
of the MPR were compromised in their ability to bind liposomes as compared to the 
MPR-less gB(730t), including gB(739t), which contains only nine MPR residues.  
However, mutation of two aromatic residues in gB(739t) to alanine (F732A/F738A) 
restored the ability of this protein to bind liposomes.  Thus, our data are consistent with a 
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critical role for the MPR in regulating exposure of the gB fusion loops thereby preventing 
premature association with lipid.   
 
MATERIALS AND METHODS 
Cells.  Mouse B78H1 melanoma cells engineered to express the gD receptor nectin-1 
(C10 cells) were grown in Dulbecco’s modified Eagle medium (DMEM) supplemented 
with 5% fetal bovine serum (FBS) and 500 µg/ml of G418. Chinese hamster ovary 
(CHO-K1) cells were grown in Ham’s F-12 medium containing 10% FBS.  CHO-K1 and 
C10 cells were kindly provided by P. G. Spear.  Sf9 (Spodoptera frugiperda) cells were 
grown in Sf900II serum-free medium (Gibco). 
 
Antibodies.   Rabbit polyclonal antibodies (PAb) R68 and R69 were raised against full-
length gB1 purified from infected cells as previously described (19).  gB-specific 
monoclonal antibodies (MAbs) SS55 and DL16 were characterized previously and 
recognize discontinuous (conformation-dependent) epitopes and are trimer-specific (6).   
 
Plasmids.  Full-length gB constructs containing deletions within the MPR, pSS1000 
[gBD(730-747)], pSS1001 [gBD(748-773)] pSS1002 [gBD(730-739)], pSS1003 
[gBD(735-744)], pSS1004 [gBD(740-749)], pSS1005 [gBD(750-759)], pSS1008 
[gBD(765-773)], were created using the QuikChange XL site-directed mutagenesis kit 
(Stratagene Cloning Systems) as described previously (11).  QuikChange primers were 
designed to “loop out” unwanted residues during amplification of template pPEP98 
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(containing the full-length gB gene from KOS, a gift of P. Spear) (42) and were as 
follows (deletion between underlined nucleotides, only forward primers shown): 
pSS1000, 5’-
CATCCACGCCGACGCCAACGCCGCGGTCGGCAAGGTGGTGATGGGC; 
pSS1001, 5’-
CGAGGGGATGGGCGACCTGGGGCGCCCCTTTGGGGCGCTGGCCGTGGG; 
pSS1002, 5’-CACGCCGACGCCAACGCCGAGGGGATGGGCGACCTG; pSS1003, 
5’-GCCGCCATGTTCGCGGGCCTGGGGCGCGCGGTCGGC; pSS1004, 5’-
GGCCTGGGCGCGTTCTTCGGCAAGGTGGTGATGGGC; pSS1005, 5’-
GACCTGGGGCGCGCGGTCGTGGTATCGGCCGTGTCG; and pSS1008, 5’-
GGCGGCGTGGTATCGGCCGTGCCCTTTGGGGCGCTGGCC.  All deletions were 
confirmed by sequencing the gB gene.  Plasmids for expression of full-length HSV 
glycoproteins (pPEP99, pPEP100, pPEP101) and those needed in the cell-cell fusion 
assay (pCAGGS/MCS, pT7EMCLuc, pCAGT7) were gifts of P. G. Spear (39, 42).   
 
Production and purification of soluble HSV glycoproteins.  To construct a baculovirus 
vector expressing the MPR-containing gB ectodomain, we PCR-amplified residues 526-
773 of gB1 from template pKBXX (containing the gB gene from KOS, a gift of S. 
Person) using primers 5´-CGGCTGCAGTTTACGTACAA (PstI site underlined) and 5´-
CGCGAGTTCAATTGGACATGAAGGAGGACAC (EcoRI site underlined). This 
fragment was cloned into PstI-EcoRI digested pCW289 (7) to generate pLH633 
[gB(773t)].  Other truncations of gB1 were generated from template pLH633 by 
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QuikChange mutagenesis, generating stop codons (underlined) at residues 740 (primer 
5´-GGCCTGGGCGCGTTCTTCTGAATTCGGTACCGACTCTGC), 750 (primer 5´-
GACCTGGGGCGCGCGGTCTGAATTCGGTACCGACTCTGC), 760 (primer 5´-
GATGGGCATCGTGGGCGGCTGAATTCGGTACCGACTCTGC). The resulting 
constructs were named pSS1010 [gB(739t)], pSS1013 [gB(749t)], and pSS1015 
[gB(759t)], respectively.  A double point mutant, gB-F732/738A(739t) (pSS1023), was 
generated from template pSS1010 by QuikChange using primer 5´-
GCCAACGCCGCCATGGCCGCGGGCCTGGGC and 5´-
GCGGGCCTGGGCGCGGCCTTCGAGGGGATGGGC (substitutions underlined) to 
sequentially add first F732A and then F738A to the coding sequence.  All mutations were 
verified by sequencing the entire gB gene. Recombinant baculoviruses were generated as 
previously described (53).  The resulting soluble gB proteins were puriﬁed with a DL16 
immunosorbent column (7).  Soluble gB-W174R(730t) was described previously (20).  
Soluble gD(306t) was purified from baculovirus-infected insect cells as detailed 
elsewhere (49, 53).   
 
Western blotting.  Purified, soluble proteins were mixed with an equal volume of 2X 
sample buffer containing either no reducing agent and 0.2% SDS (“native” conditions) or 
200mM dithiothreitol and 2% SDS (“denaturing” conditions) (13). Proteins from 
denatured samples were also boiled for 5 min before electrophoresis.  For full-length 
proteins, C10 cells were grown on 6-well plates and transfected with the desired plasmids 
according to the GenePORTER protocol (Gene Therapy Systems, Inc.).  At 24-48 h post-
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transfection, cells were lysed in 200 mL of lysis buffer (10 mM Tris (pH 8), 150 mM 
NaCl, 10 mM EDTA, 1% NP-40, 0.5% deoxycholic acid), 5 mL of which was used for 
electrophoresis (denaturing conditions).  All proteins were resolved by polyacrylamide 
gel electrophoresis and transferred to nitrocellulose for Western blotting.  
 
Fusion assay.  To detect cell-cell fusion, we used a previously described luciferase 
reporter assay (32, 39, 42).  Briefly, CHO-K1 cells were grown in 24-well plates and 
transfected with plasmids encoding T7 RNA polymerase (pCAGT7), gD (pPEP99), gH 
(pPEP100), and gL (pPEP101) and either wild-type gB (pPEP98), mutant gB, or empty 
vector (pCAGGS/MCS). To prepare receptor-expressing cells, CHO-K1 cells growing in 
six-well plates were transfected with a plasmid encoding the firefly luciferase gene under 
control of the T7 promoter (pT7EMCLuc) and a plasmid encoding HVEM (pSC386). Six 
hours post-transfection, receptor-expressing cells were trypsinized and added to the 
glycoprotein-expressing cells. At 18h post-cocultivation, cells were washed with PBS, 
lysed in reporter lysis buffer (Promega), and frozen. Finally, the extracts were thawed and 
mixed with 100 µl of luciferase substrate (Promega) and immediately assayed for light 
output by luminometry. 
 
CELISA.  To detect gB cell surface expression, we used a modification of a cell-based 
enzyme-linked immunosorbent assay (CELISA).  CHO-K1 cells growing in 96-well 
plates were transfected with pCAGT7, pPEP99, pPEP100, pPEP101, and a plasmid 
encoding either wild-type gB (pPEP98), mutant gB, or empty vector (pCAGGS/MCS).  
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Forty nanograms of each plasmid/well and 0.5 µl of Lipofectamine 2000 (Invitrogen) 
were used.  Cells were exposed to the DNA-Lipofectamine 2000 mixture for 5 h, after 
which the mixture was replaced with growth medium. Cells were grown overnight, fixed 
in 3% paraformaldehyde, and rinsed with PBS.  Cells were then incubated for 1 h with 
PAb R68 diluted in 3% bovine serum albumin-PBS and incubated for 30 min with goat 
anti-rabbit antibodies coupled to horseradish peroxidase.  Cells were rinsed with 20 mM 
citrate buffer (pH 4.5), incubated with peroxidase substrate (Moss, Inc.), and the 
absorbance at 405 nm was recorded using a microtiter plate reader. The absorbance 
values of cells transfected with the empty vector pCAGGS/MCS was subtracted and data 
were normalized to WT gB. 
 
Liposome flotation assay.  Liposome flotation assay conditions were adapted from 
previously described methods (15, 20, 27). Liposomes were purchased from Encapsula 
Nanosciences (Nashville, TN) at a size of 400 nm, containing a 1.7:1 molar ratio of soy-
phosphatidylcholine to cholesterol.  Briefly, purified soluble gB (1 µg), liposomes (25 
µg), 1x protease inhibitor cocktail (Roche), and 15 µl of 200 mM sodium citrate were 
combined and the final reaction volume was adjusted to 50 µl with PBS.  Protein-
liposome mixtures were then incubated at 37°C for 1 h.  To eliminate unwanted 
electrostatic protein-lipid associations, mixtures were incubated with 1 M KCl for 15 min 
at 37°C before being loaded at the bottom of a sucrose gradient.  Mixtures were adjusted 
to 40% sucrose in a final volume of 500 µl and overlaid with 4 ml of 25% sucrose-PBS 
and 500 µl of 5% sucrose-PBS.  The gradients were centrifuged for 3 h in a Beckman 
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SW55Ti rotor at 246,000 x g at 4°C.  Seven equal fractions (approximately 700 µl each) 
were collected, starting from the top of the gradient. Dot blotting onto nitrocellulose was 
performed using 225 µL per fraction and probed with the anti-gB PAb R68. 
 
Surface plasmon resonance (biosensor) experiments to detect gB-liposome binding.  
Surface plasmon resonance (SPR) experiments were performed using a Biacore 3000 or 
Biacore X100 optical biosensor (GE Healthcare, Biacore Life Sciences) at 25°C.  Filtered 
and degassed HBS-N buffer (10 mM HEPES pH 7.4, 150 mM NaCl) was used in all 
liposome association experiments. We used an L1 sensor chip (Biacore) as it has a 
hydrophobic surface capable of binding liposomes.  Liposomes were purchased from 
Encapsula Nanosciences (Nashville, TN) at a size of 400 nm, containing a 1.7:1 molar 
ratio of soy-phosphatidylcholine to cholesterol.  To prepare the chip surface for liposome 
binding, it was washed sequentially with 20 µl of 1% octyl-β-D-glucopyranoside, 20 µl 
of 0.5% SDS, 10 µl of 1% octyl-β-D-glucopyranoside, and 10 µl of 30% ethanol.  
Liposomes (1 mM, diluted in HBS-N) were injected until the chip was saturated, giving a 
signal of approximately 8500 response units (RU).  Once bound, the liposomes remained 
on the chip and there was no appreciable dissociation (no measurable off-rate).  Purified 
soluble proteins diluted in HBS-N buffer were then individually injected at various 
concentrations (achieved by dilution in HBS-N buffer) at a flow rate of 5 mL/min.  After 
injection of the soluble protein was complete (typically 20 mL for 240 s), the RU was 
recorded and used to determine the level of protein binding.  After each protein injection 
the surface preparation protocol was performed to remove protein and liposomes from the 
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chip, regenerating the surface to the RU baseline.  
 
Gel filtration/ size exclusion chromatography.  Size exclusion chromatography of gB 
(52) was performed on a AKTApurifier equipped with a Superdex S200 (24 mL) column 
(GE Healthcare) equilibrated with phosphate-buffered saline.  The Superdex column was 
calibrated by using thyroglobulin (669 kDa), ferritin (440 kDa), aldolase (158 kDa), 
conalbumin (75 kDa), ovalbumin (43 kDa), carbonic anhydrase (29 kDa), ribonuclease A 
(14 kDa), and aprotinin (6 kDa); blue dextran was used to determine the void volume 
(GE Healthcare).  For each sample, 5 mL of each fraction was separated by SDS-PAGE 
and the high molecular weight, trimeric, and monomeric forms of gB were visualized by 
Western blotting with an anti-gB PAb (R68).  Fractions that contained mostly 
trimers/monomers were pooled and tested by SPR for liposome binding. 
 
RESULTS 
The crystal structure of HSV-1 gB (Figure 2-1A) was solved using a soluble form 
of gB truncated at amino acid 730 (gB730t) (23) to avoid the hydrophobic membrane 
proximal residues (730-773) just upstream of the transmembrane region (TMR) that 
might impair crystal formation (10, 40).  The form of HSV gB used for crystallization 
ended at amino acid 730, leaving the fusion loop region exposed (23).  Residues 
downstream of amino acid 730 were initially excluded for crystallization trials due to 
their elevated hydrophobicity, which could impede crystal formation.  We hypothesized 
that these 43 amino acids, constituting the membrane proximal region (MPR) of gB, 
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obscure the fusion loops and prevent them from interacting with a target membrane until 
gB is “activated” for fusion (21).  We assumed that these residues are in close proximity 
to the fusion loops based on the gB crystal structure (Figure 2-1A, yellow).     
 
MPR deletions impair HSV gB transport.  To determine if the MPR regulated the 
ability of the fusion loops to associate with membranes, we first constructed seven MPR 
deletion mutants (within the context of full-length gB) (Figure 2-1B).  The N-terminal 
half of the MPR was deleted in gBD(730-747) and the C-terminal half was deleted in 
gBD(748-773).  The remaining mutants contained smaller deletions spanning the MPR: 
gBD(730-739), gBD(735-744), gBD(740-749), gBD(750-759), and gBD(765-773).  All 
mutants were efficiently expressed in B78-C10 cells, as seen by Western blots of total 
cell lysates (Figure 2-2A).  However, when intact transfected cells were tested by 
CELISA, all of the deletion mutants were poorly expressed (<30% that of gB-WT) on the 
cell surface, indicating that although the mutants were expressed they were inefficiently 
transported to the cell surface (Figure 2-2B, black bars).  Consequently, none were able 
to function in a cell-cell fusion assay (Figure 2-2B, gray bars).  Thus, as seen in other 
studies (43, 62), deletion of even small sections of the gB MPR has a negative impact on 
proper protein folding and transport. 
 
Construction of soluble, MPR-containing gBs.  To characterize the biochemical 
properties of the gB MPR, we created and purified a series of soluble gB ectodomains (no 
TMR or endodomain) that lack portions of the MPR.  We previously characterized the gB  
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Figure 2-1.  (A) Surface representation of the gB trimer. Residues of FL1 (from all 3 
monomers) are shown in pink while those of FL2 are shown in blue. The C-termini of the 
solved gB monomers are highlighted (yellow).  The unsolved MPRs (amino acids 730-
773) of each protomer are represented as dashed, tan lines emanating from the gB 
monomer C-termini.  FL1 and FL2 of one protomer are labeled in the bottom view of the 
trimer. (B) Stick figure of a gB protomer, showing its structural domains (Roman 
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numerals). FL1 and FL2 are indicated with arrows, colored as in (A).  Amino acid 
numbers are shown along the top.  The MPR is highlighted in tan and its residues are in 
expanded view below.  Residues that were mutated in this study are highlighted in bold 
and starred.  Deletion mutants are designated as boxes and aligned below the MPR amino 
acids, with a dashed line indicating deleted residues in the full-length protein. (C) Stick 
representation of the soluble C-terminal truncation mutants generated in this study.  The 
point mutations F732A and F738A are indicated as black bars.  Sig, signal sequence. 
TMR, transmembrane region. 
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ectodomain gB(730t), lacking all of the MPR, and found that it remains oligomeric, 
retains all of its major epitopes, and associates with liposomes  (12, 20, 23).  Here, we 
compared it with both soluble forms of gB bearing partial MPRs [gB(759t), gB(749t), 
gB(739t)] and a complete ectodomain containing the full MPR, gB(773t) (Figure 2-1C).  
All were expressed and secreted into the supernatant of baculovirus-infected cells (Figure 
2-3A).  When the proteins were examined on a non-denaturing gel, all contained both 
monomeric and trimeric forms of gB (Figure 2-3A, bottom panel).  Although all of the 
truncated proteins were recognized by MAbs with trimer-specific, conformation-
dependent epitopes (DL16, SS55), indicative of proper protein folding, gB(759t) 
appeared to react less well (Figure 2-3B).  All MPR-containing gBs also retained their 
ability to react with MAbs with epitopes in each functional region (data not shown). 
 
Presence of the MPR affects binding of soluble gB to liposomes.   
(i) Analysis by liposome flotation.  We previously observed that the MPR-less 
soluble gB(730t) interacts in vitro with liposomes when the two are mixed (12, 20), 
presumably recapitulating the interaction of the gB fusion loops with the cell membrane 
during virus-cell fusion.  Initially, we used the liposome flotation assay to assess whether 
the MPR, or portions of it, interfered with this interaction. Purified soluble proteins were 
individually incubated with liposomes (phosphatidylcholine-cholesterol) at 37oC.  Each 
protein-liposome mixture was then adjusted to 40% sucrose, layered beneath a sucrose 
step gradient and centrifuged to allow the liposomes and any associated proteins to float 
to the top, while proteins that failed to bind liposomes would remain at the bottom of the  
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Figure 2-2.  Characterization of gB MPR deletion mutants.  (A)  Full-length MPR 
mutants were expressed in mammalian cells and total cell extracts were analyzed by 
denaturing Western blot.  Blots were probed with the anti-gB PAb R68.  (B) Protein 
surface expression as detected by CELISA (black bars).  Transfected CHO-K1 cells were 
fixed with 3% paraformaldehyde, then incubated with the anti-gB PAb R69 and GAM-
HRP.  Cells transfected with empty vector DNA were used as a negative control, and this 
value was subtracted from the other experimental samples.  Quantitative cell-cell fusion 
assay (gray bars) was performed with co-cultivation of target CHOK1 cells (expressing 
the luciferase protein and the HSV receptor HVEM) with effector CHO cells (expressing 
T7 polymerase, gD, gH and gL, plus either WT gB, mutant gB, or empty vector DNA).  
Cell extracts were tested for light production 18 h later.  Percent WT was calculated as 
follows: for CELISA = (sample absorbance / WT absorbance) x 100; for fusion assay = 
(relative light units (RLU) of test sample/ RLU of WT) x 100. 
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gradient.  The liposome-containing (top) fractions were analyzed by dot blot using a 
polyclonal anti-gB antibody for visualization (Figure 2-3C).  As previously observed 
(20), gB(730t) was not detected in the upper fractions in the absence of liposomes, but 
floated to the top of the gradient in their presence.  In the case of the MPR-containing 
gBs, the ability to co-associate with liposomes decreased markedly.  The data shown in 
Figure 2-3C suggests there might be a small difference in binding between gB(739t) and 
gB(773t) but this type of analysis is not quantitative.  Therefore, we turned to surface 
plasmon resonance (SPR, biosensor) to get a more accurate measurement of liposome 
binding (8).  
 
(ii) Analysis by SPR/biosensor.  Liposome are able to bind to the lipophilic L1 chip of 
the Biacore instrument, which detects mass changes by SPR (1).  In this assay, liposomes 
were first injected and flowed across an L1 chip surface and liposome binding, i.e. the 
mass change due to binding, was detected as an increase in response units (RU) (Figure 
2-4A).  Approximately 8500 RU of liposomes were sufficient to saturate each flowcell of 
the chip and this amount was used in each experiment.  Next, each gB protein was added 
and allowed to flow across the chip for 240 s.  An increase in RU was indicative of 
protein binding to the immobilized liposomes.  It is this second response curve (gB-
liposome binding, Figure 2-4A, framed) that is shown in Figs. 4B-E.  To set up the 
appropriate binding conditions for our proteins, we first compared gB(730t), known to 
bind liposomes in a flotation assay, to both the fusion loop mutant gB-W174R(730t) and 
to gD(306t), two proteins which do not bind liposomes (20).  As expected, gB(730t) 
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Figure 2-3.  Soluble gB MPR-containing proteins are expressed and folded correctly.  
(A) Four gB mutants (739t, 749t, 759t, 773t) were cloned and expressed in a baculovirus 
expression system as secreted forms each truncated after the indicated amino acid.  
Proteins were detected with the PAb R69 and visualized by denaturing (top panel) or 
“native” (bottom panel) Western blot.  (B) Reactivity of gB MPR-containing proteins 
with the conformation-dependent MAbs SS55 (top panel) or DL16 (bottom panel) via 
“native” Western blot.  Molecular weight standards are shown on the left in kilodaultons 
for both (A) and (B).  (C)  Liposome flotation assay. Purified soluble glycoproteins were 
incubated with liposomes for 1 h at 37oC.  Samples were then adjusted to 1M KCl, 
incubated for an additional 15 min and then layered beneath a discontinuous 5-40% 
sucrose gradient, centrifuged for 3 h, and then fractionated. The top, liposome-containing 
fraction was analyzed by dot blot with the PAb R68.    
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readily bound to the immobilized liposomes, as indicated by the increase in RU, while 
gB-W174R(730t) and gD(306t) did not (Figure 2-4B).  Furthermore, gB(730t) bound to 
liposomes in a dose-dependent manner, showing an increase in RU from 0.08 mM to 5 
mM of protein (Figure 2-4C).  Thus, we demonstrated that biosensor analysis yields 
reproducible and quantitative data on membrane binding by soluble glycoproteins. 
The liposome binding capacity of the MPR-containing gB forms was then 
analyzed within the same range of protein concentrations as used for gB(730t).  We 
found that gB(773t), which contains the complete MPR, bound to liposomes in a dose-
dependent manner, albeit at a much lower level than seen for gB(730t) (compare Figure 
2-4C and 2-4D).  Although, curve-fitting for kinetic analysis (1) was not possible with 
our data sets, possibly due to complications associated with liposome binding.  None of 
the MPR-containing gB truncations bound to liposomes as well as gB(730t), although all 
exhibited a low level of measurable binding (Figure 2-4E), especially when compared to 
the two negative controls (Figure 2-4B).  Of importance, we detected no significant 
differences in gB-liposome binding between proteins containing portions of or the 
complete MPR [gB(739t), gB(749t), gB(759t), or gB(773t)].  Upon averaging the 
maximum binding from several experiments (i.e. after two minutes of injection of 0.16 
mM gB) we determined that gB(739t) bound to liposomes at a level that was 35% of that 
of gB(730t), gB(749t) 38%, gB(759t) 29%, and gB(773t) 46% (Figure 2-4F).  In 
comparison, the negative control gB-W174R(730t) bound at 18% that of gB(730t).  The 
data show that the presence of the first nine amino acids of the MPR (residues 731-739) 
are sufficient to significantly diminish the association of gB with liposomes.   
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Figure 2-4.  Liposome binding assay, biosensor analysis.  (A) Liposomes are injected 
and flowed across flowcell (Fc) 1 and Fc2, with binding at saturation [~8500 RU 
(response units)].  Soluble gB(730t) is then injected across Fc2 at 5 mL/min for 240 s and 
binding to liposomes is measured as an increase in RU; this portion of the graph (boxed) 
is shown and analyzed in subsequent figures. A double-slash denotes a break in the x-axis 
(no injections were performed during that time period).  (B) Response curve showing 
binding of control proteins gB(730t) (positive control), fusion loop mutant gB-
W174R(730t) (negative control), and soluble gD (negative control).  Two-fold serial 
dilutions of gB(730t) (C) or gB(773t) (D) were injected across the liposome-coated flow 
cell at 10 µl/min for 2 minutes to evaluate ligand-liposome association. After each 
injection the surface preparation protocol was performed to remove protein and 
liposomes from the chip, regenerating the surface to the RU baseline. (E) Each soluble 
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protein (156 nM) was flowed across an L1 chip containing immobilized liposomes as 
described in (A).  Flow rate was 5 mL/min.  (F) Bar graph representation of gB-liposome 
binding via biosensor.  The graph displays an average of at least 3 separate experiments, 
with samples presented as percent binding of gB(730t) (set at 100%).  Error bars 
represent percent error. 
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The decrease in liposome binding is not due to aggregation of the MPR mutants.  
Our data suggest that the MPR specifically obscures the fusion loops and prevents their 
interaction with lipids; however, another possibility is that the hydrophobic character of 
the MPR promotes gB aggregation, possibly obscuring the fusion loops non-specifically 
and preventing binding to membranes/lipids.  To address this issue, we used gel filtration 
to separate out any high molecular weight (HMW, i.e., aggregated) gB species from those 
fractions predominantly containing gB trimers (Figure 2-5, left panels).  We then tested 
the pooled trimeric fractions for liposome binding using SPR (Figure 2-5, right panels).  
Each protein was chromatographed by size exclusion on a sepharose column as 
previously described (52).  Multiple fractions were obtained and evaluated by Western 
blotting and a representative group of data is shown in Figure 2-5.  The bulk of gB(730t) 
eluted in the trimeric fractions (boxed in Figure 2-5A) and much less was found in the 
earlier, HMW fractions.  In contrast, the bulk of the MPR-containing gBs (represented by 
gB(749t) in Figure 2-5B) was in the HMW fractions (Figure 2-5B and data not shown).  
For each protein, the trimeric fractions were pooled and equal concentrations of protein 
were injected over the liposome-L1 chip.  As expected, the trimeric pool of gB(730t) 
bound well to liposomes (Figure 2-5A, right panel).  Importantly, the trimeric pools of 
MPR-containing gBs were unable to bind liposomes, as exemplified by gB(749t) (Figure 
2-5B).  Indeed, the modest binding of unfractionated gB(749t) was substantially reduced 
by removal of the HMW material, suggesting that its binding was due to non-specific 
association of aggregated material.  Together, our results indicate that aggregation of 
MPR-containing gB does not prevent liposome binding, but instead indicate that MPR-  
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Figure 2-5.  Gel filtration/size exclusion chromatography of (A) gB(730t) and (B) 
gB(773t).  Fractions containing mostly trimeric (boxed in the Western blot) species were 
tested via biosensor for liposome binding at 156nM gB for 240 s.  Fractions containing 
high molecular weight species (HMW, samples to the right of the box on the Western 
blot) were excluded from study.  “Total” refers to the gB sample before it underwent gel 
filtration. 
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containing gB trimers are specifically compromised in their liposome-binding ability as 
compared to gB(730t), presumably due to the FLs being obscured by the MPR.   
 
A double point mutation within the MPR restores gB-liposome binding.  Because 
mutants such as gB-W174R(730t) do not bind liposomes (Figure 2-4B), it is clear that 
association of gB(730t) with lipid membranes occurs via its fusion loops (20).  Here we 
 have shown that the first nine residues of the MPR are sufficient to reduce this binding 
(Figure 2-4E-F).  Among residues 731-739 (MFAGLGAFF) there are four hydrophobic 
amino acids: F732, L735, F738, and F739.  These residues could stabilize the MPR and 
through their side chains possibly form contacts with the fusion loops or surrounding 
residues.  To address the role of these nine residues, we selected F732 and F738, as based 
on our model they were most likely to form such contacts (Figure 2-6A), and mutated 
them to alanine, creating a double point mutant within the context of gB(739t), gB-
F732/738A(739t) (Figure 2-1C).   We predicted that this mutant would prevent putative 
interactions between the MPR and the underlying residues of the fusion loops (modeled 
in Figure 2-6A) and therefore might improve gB-liposome binding in the context of 
gB(739t).  The mutant protein was recognized by MAbs against conformation-dependent 
epitopes, indicating that it was properly folded (Figure 2-6B).  Unlike its parent protein 
gB(739t), very few HMW species were observed when gB-F732/738A(739t) was 
analyzed by gel filtration (Figure 2-6C).  Interestingly, biosensor analysis revealed that 
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gB-F732/738A(739t) bound liposomes much better than gB(739t) and nearly as well as 
gB(730t) (Figure 2-6D).  These data suggest that the phenylalanine mutations 
compromise the ability of the MPR to shield the fusion loops, permitting their exposure 
and subsequent association with lipid membranes.   
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Figure 2-6.  (A) Model of a possible interaction between the gB fusion loops and MPR.  
The gB trimer is rendered in cartoon form in gray, focusing on the fusion loops (FL1 
pink, FL2 blue) and C-terminus of one of the protomers (H724, yellow spheres).  Side-
chains of both fusion loops are shown.  The MPR is depicted as a gold dashed line, with 
the aromatic residues F732 and F738 represented as circles.  (B) Native Western blot of 
soluble gB proteins, probed with the indicated MAbs.  Molecular weight standards are 
shown between the two blots in kilodaultons.  (C) Native Western blot of gel filtration 
fractions as described in Figure 2-5.  (D) gB-liposome binding assay (biosensor analysis) 
as described in Figure 2-4A.  Soluble gB(730t) served as the positive control and soluble 
gD as the negative control. 
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DISCUSSION 
Both class I and class II viral fusion proteins have their fusion peptides/loops 
buried inside the molecule in the pre-fusion form (59).  Here, we suggest that for the class 
III fusion protein HSV gB, the MPR serves this role.  Soluble gB ectodomains containing 
various lengths of the MPR were all reduced in liposome binding as compared to the 
MPR-less gB(730t); this included gB(739t), which contains only nine MPR residues.  
Mutation of two phenylalanine residues to alanine (F732A/F738A) in the gB(739t) MPR 
sequence restored the ability of this protein to bind liposomes.  We believe that 
substitution of alanine residues for F732 and F738 disrupts the association of the MPR 
with the fusion loops, thereby allowing the fusion loops to be unimpeded and now able to 
bind lipid membranes.  Our data are consistent with a role for the MPR in regulating the 
lipid association capability of the gB fusion loops.   
 
Use of biosensor to evaluate gB-liposome binding.  To study gB-liposome interactions, 
we used SPR/biosensor in addition to our previously described liposome flotation assay 
(12, 20).  SPR has been used in the HIV field to dissect antibody-MPR (of the viral 
fusion protein gp41)-liposome binding (reviewed in (22)).  Here we have applied it to the 
HSV fusion protein, gB.  Since liposomes remain as individual vesicles when bound to an 
L1 sensor chip (2), as they do with liposome flotation, the two assays should be in 
agreement to measure protein-liposome interactions.  Measuring liposome binding by 
SPR has several advantages over the standard flotation assay.  First, it is far easier and 
faster to measure binding, as multiple samples can be analyzed on a single chip.  
	  
	  
	  
92	  
Moreover, SPR allows for real-time measurement of gB-liposome binding whereas the 
flotation assay relies on a secondary observation (antibody binding on a dot or Western 
blot) taking place approximately 6 hours after the proteins and liposomes are co-
incubated.  The quantitative nature of the biosensor also allowed us to compare percent 
binding of each experimental sample to wild type [in this case, MPR-containing gBs, gB 
fusion loop mutants, or gD to gB(730t)].   
 
The HSV gB MPR is sensitive to mutation.  Unlike the MPRs of other fusion proteins 
(24, 34, 50, 57, 64), the MPR of gB is particularly sensitive to deletion (43) (Figure 2-2).  
While our data point to MPR residues 731-739 as having a role in modulating fusion, the 
remainder of the MPR remains essential at the very least for protein folding and 
transport; this may be due to hydrophobic residues in the FLs or the MPR being 
recognized by ER chaperones, leading to ER retention.  While deletions within the gB 
MPR are detrimental in the context of full-length proteins, deletion of the MPR in soluble 
gB ectodomains does not affect protein expression in our baculovirus system (nor does 
inclusion of the MPR).  Although the soluble gB ectodomain is believed to be in a post-
fusion form, we are hypothesizing that the MPR functions as a fusion loop “mask” even 
when gB is in a pre-fusion form prior to fusion.  In fact, a pre-fusion structure of VSV G 
(47) and model of EBV gB (5) suggest that structural domain I, which contains the fusion 
loops, remains in the same relative conformation both pre- and post-fusion, suggesting 
that this strategy is sound.  In further support, the FLs remain in close proximity to the 
ectodomain C-terminus (and therefore MPR) in both pre- and post-fusion forms. 
	  
	  
	  
93	  
Previously characterized MPR point mutants in full-length HSV-1 gB were found 
to be complementation-defective for gB-null virus and exhibited a slower rate of entry, 
although two of the four mutants characterized were also defective in protein trafficking 
(58).  None of these point mutants were within residues 731-739, which we have defined 
as having an effect on liposome binding.  In additional experiments, we found that 
separate mutation of F732A or F738A (in the context of full-length gB) had no effect on 
cell surface expression yet each had a negative effect on cell-cell fusion (data not shown).  
This result is in accordance with our data from the soluble gB-F732/738A double mutant.  
We predict that the decrease in cell-cell fusion would be explained by premature 
“triggering” of the FL, due to disruption of important MPR contacts required to maintain 
gB in a pre-fusion form.  It is of note that gB residue F738 is conserved in all 
alphaherpesviruses (23, 58).   
 
Role of the MPR in other viruses.  MPR mutations in both VSV G (24) and baculovirus 
gp64 (34) abolish fusion but do not affect cell surface protein expression, indicative of a 
role for the MPR in the function of these proteins.  In the VSV G, the amino acids 
upstream of the TMR in the linear sequence are modeled as “stretching” from the top of 
the protein structure (crown) down to the transmembrane region in the post-fusion 
structure (46), and this region is hypothesized to act as a flexible tether for positioning of 
the fusion protein  between the viral and cellular lipid bilayers (45).  Unlike the gB fusion 
loops, those of baculovirus gp64 are hypothesized to have a second role, in virus-cell 
attachment (26, 63).  Therefore, one would expect the triggering of gp64 fusion loops 
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would occur earlier in the pathway (to facilitate virus-cell attachment) than for gB (to 
initiate virus-cell fusion), leaving the MPRs of gp64 and gB to perhaps serve different 
functions. 
 
How might the gB MPR and FLs work together?  There are several hypotheses on 
what triggers gB activation, thereby exposing the fusion loops and promoting fusion of 
the virus and cell membranes (59).  A low pH, “histidine switch” model has been 
proposed for gp64 (33) and was also tested for HSV gB by Heldwein and colleagues (54), 
who found that only one of the two fusion loops (FL2, containing H263) changed 
conformation at low pH; the bulk of the soluble gB(730t) remained unchanged in 
structure.  Although this work was done on soluble gB (thought to be in the post-fusion 
conformation), it fits with a pre-fusion model of EBV gB which predicts that domain I 
(containing the FLs) retains its fold between pre- and post-fusion forms (5).  Therefore, 
we suggest that the change in FL2 in response to low pH is sufficient to disengage the 
FLs from the MPR and expose them to lipids.  Indeed, when gB(739t) was incubated at 
pH 5, its ability to bind liposomes increased to 68% that of gB(730t) (data not shown).  
However, we need to keep in mind that HSV gB also functions at neutral pH in certain 
cell types (17, 36, 38, 60) and activation may occur through gHgL-gB interactions (3, 4), 
and perhaps even the gB cytoplasmic tail (51).  Regardless of these possibilities, our data 
highlight the importance of the MPR in regulating exposure of the gB fusion loops and 
suggest they play a critical role in maintaining gB in an inactive form, i.e. unable to insert 
its fusion loops into a target membrane until it is triggered to execute virus-cell fusion. 
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CHAPTER 3 
GENERAL DISCUSSION 
 HSV entry is a highly regulated process that requires four viral glycoproteins; gD, 
gH/gL heterodimer, and gB (8, 11).   The crystal structures of these core fusion 
components have been solved and provide detailed information about their structure and 
function, but much work still needs to be completed to fully understand the HSV entry 
process (4, 5, 12, 14).  The gB MPR was not included in the crystallized gB construct 
[gB(730t)], so its structural organization is not known (12).  In this thesis I investigated 
the role of the gB MPR in the function and  regulation of fusion.   
As described in Chapter 2, using a series of gB deletions, truncations, and point 
mutations we found that the presence of as few as nine MPR residues [gB(739t)] resulted 
in a decrease in gB’s ability to associate with liposomes.  We also found mutation of two 
aromatic residues in gB(739t) to alanine (F732A/F738A) restored liposome binding.  In 
comparison, MPR-less gB [gB(730t)] bound liposomes well via its fusion loops as was 
observed in our lab’s previous work (10).  These data are consistent with a critical role 
for the MPR in regulating exposure of the gB fusion loops, thereby preventing premature 
association with lipid.  
Analysis of the gB ectodomain crystal structure suggests it represents the post-
fusion form of the fusion protein based on structural homology with the VSV G post-
fusion structure (12, 17-19).  Interestingly, in the VSV G pre-fusion and post-fusion 
structures the FL containing domain undergoes little intra-domain conformational 
rearrangement.  In both the pre-fusion and post-fusion structures the VSV G fusion loops 
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remain exposed and appear accessible to interact with membranes while the entire 
domain maintains its overall structure (17-19).  Given the structural homology between 
post-fusion structures of the class III fusion proteins VSV G and HSV gB, we 
hypothesized that VSV G could be used to model and predict the HSV gB pre-fusion 
structure.  A similar approach was used to create a hypothetical model of pre-fusion EBV 
gB, but this model has not yet been verified by a pre-fusion EBV gB crystal structure (3).  
A hypothetical HSV gB pre-fusion organizational model was proposed by John Gallagher 
and J. Charles Whitbeck in our laboratory (Figure 3-1A).  This model predicts the general 
conformational changes from HSV gB pre-fusion to post-fusion through a pre-hairpin 
intermediate (Figure 3-1).   
The class III fusion protein VSV G’s pre-fusion structure revealed exposed fusion 
loops (19).  We hypothesize that HSV gB, and as noted in the previously published 
model of EBV gB, pre-fusion structures are similar to VSVG, and they will also have 
exposed fusion loops (3, 17, 19, 22).  This is in contrast with the internally buried fusion 
peptides/loops of class I and class II fusion proteins.   
Our proposed pre-fusion gB model lacks the MPR (Figure 3-1A), as the gB post-
fusion structure does, but we hypothesized in chapter 2 that the HSV MPR functions to 
“mask” the fusion loops from premature exposure to membrane (Figure 2-6A).  MPR 
masking of the gB FLs adds another potential layer of regulation to already the complex 
HSV entry process.   
 
 
	  
	  
	  
107	  
 
 
  
 
Figure 3-1.  Model of conformational changes predicted to occur between the pre-fusion 
and the post-fusion forms of HSV gB.  (A) Shows the pre-fusion form of gB modeled 
after the published pre-fusion form of VSV G.  (B) and (C) depict changes predicted to 
occur as structural domain 1 (blue; including the fusion loops) disengages from the MPR 
(not shown) and extends toward the target (host) cell membrane.  Arrows indicate 
direction of movement.  (D) shows the fully extended (pre-hairpin) intermediate.  Here 
the fusion loops are predicted to insert into the target membrane.  (E) represents the post-
fusion structure of gB based on the published crystal structure. Figure provided by John 
Gallagher and J. Charles Whitbeck.  
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Regulation of the gB transition from pre-fusion to post-fusion resulting in 
membrane fusion must require an activation trigger leading to FL exposure.  In chapter 2 
we suggest a low pH “histidine” switch model as described by Stampfer et al. (21) 
resulting in a shift in FL2 disengaging the MPR and exposing the FL for membrane 
interaction.  This low pH model is attractive due to the FL2 conformational change noted 
above, but it does not fit all HSV entry situations.  Since HSV does not require low pH to 
enter all cell types, as described in the introduction, another mechanism is needed for gB 
activation. The interaction between gB and gH/gL could serve to induce a conformational 
change in gB that releases the MPR from the FL allowing cellular membrane binding and 
initiation of fusion reaction (1, 2).   
After gB activation and FL exposure the predicted conformational changes 
proceed from the pre-fusion form through an extended pre-hairpin intermediate to folds 
to the solved post-fusion gB structure pulling the viral and cellular membranes together 
(Figure 3-1).   Our proposal includes global rearrangements of the gB domains in relation 
to each other and few changes within domains themselves.  Interestingly, in response to 
low pH the class II fusion protein TBEV E also undergoes large movements of domains, 
but few conformational changes occur within the individual domains during transition 
from a dimeric state to a trimeric post-fusion state.  Many conclusions can be drawn 
through analysis of our biochemical assays, functional assays, and comparative fusion 
protein analysis.  Ultimately, HSV gB’s ability to facilitate membrane fusion will be best 
understood by evaluation of a pre-fusion structure, and hopefully intermediate structures 
as well. 
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Future directions 
 In this thesis the role of the MPR has been investigated to provide insight into the 
regulation and exposure of gB FLs.  Not surprisingly this work has generated many new 
questions.  To answer these questions a continuation of the detailed analysis of the 
interaction between the MPR and the FLs is needed.  Using our biochemical and 
functional assays in combination with an expanded array of MPR and FL mutations we 
may be able to further identify key interactions between the MPR and FLs.  The further 
refinement of the gB MPR interaction with the FLs may reveal important steps in the 
regulation of gB-membrane interactions and fusion mechanism.   
Arguably the greatest future insight into gB function would be delivered by the 
capture of a pre-fusion structure.  Inclusion of the MPR into this structure would be ideal, 
but give the high hydrophobicity that prompted the MPRs exclusion from the post-fusion 
structure its inclusion is unlikely (12).  Lacking global gB structural data we could build 
more modestly on our MPR structural knowledge using long peptides encompassing the 
MPR sequence for crystallization and structural analysis as was performed for HIV-1 
gp41 MPER (15, 20).  Using a variety of techniques including circular dichroism, cryo-
electron microscopy, SPR we may determine further details of the gB MPR structure and 
function by analyzing a MPR peptide.   
To continue the investigation of gB in the absence of a pre-fusion structure we 
have initiated the development of a series of polyclonal antibodies to the gB MPR and 
FLs.  These reagent could provide a wealth of information about the accessibility and 
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functional interactions between the FLs and MPR during the fusion process.  Few 
neutralizing antibodies to viral fusion loops/peptides have been identified, but several 
reports in Dengue virus and related flaviviruses have identified a neutralizing antibody 
that maps to their fusion peptides (6, 7).  We have preliminary data that support the 
successful development of a polyclonal antibody to the HSV FLs (data not shown).   
Similarly, MPR specific antibodies have rarely been reported.  In the HIV-1 gp41 
neutralizing antibodies that map to the MPER (membrane proximal external region) have 
been identified in several patients.  Analysis of these neutralizing antibodies has 
expanded the understanding of gp41s role in fusion and lipid interaction (9, 13, 16).  
Development of an antibody against the HSV gB-MPR could provide a wealth of 
information leading to a better understanding of the MPRs interaction, structure, and 
function.  
 Finally, future analysis of FLs and MPR needs to be evaluated in context of the 
entire HSV entry complex.  Given HSV’s requirement for four glycoproteins gD, gH/gL, 
and gB, for both entry and virus-induced cell fusion, the continued dissection of this 
mechanism will be a continuing challenge. Ultimately, the detailed structural and 
functional understanding of HSV entry will have long-range implications contributing to 
the framework for future therapeutics and vaccine development across the herpesvirus 
families. 
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APPENDIX 
 
Autophagy is an essential component of Drosophila immunity against  
vesicular stomatitis virus 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reprinted from Publication Immunity, 30(4), S. S. Shelly, N. Lukinova, S. Bambina, A. 
Berman, S. Cherry, Autophagy is an essential component of Drosphila immunity against 
vesicular stomatitis virus, 588-598, Copyright (2009), with permission from Elsevier.  
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ABSTRACT 
Intrinsic innate immune mechanisms are the first line of defense against pathogens and 
exist to control infection autonomously in infected cells. Here, we showed that 
autophagy, an intrinsic mechanism that can degrade cytoplasmic components, played a 
direct antiviral role against the mammalian viral pathogen vesicular stomatitis virus 
(VSV) in the model organism Drosphila. We found that the surface glycoprotein, VSV-
G, was likely the pathogen-associated molecular pattern (PAMP) that initiated this cell-
autonomous response. Once activated, autophagy decreased viral replication, and 
repression of autophagy led to increased viral replication and pathogenesis in cells and 
animals. Lastly, we showed that the antiviral response was controlled by the 
phosphatidylinositol 3-kinase (PI3K)-Akt-signaling pathway, which normally regulates 
autophagy in response to nutrient availability. Altogether, these data uncover an intrinsic 
antiviral program that links viral recognition to the evolutionarily conserved nutrient-
signaling and autophagy pathways. 
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INTRODUCTION 
Detection and clearance of viruses by the innate immune system relies on several 
distinct and essential pathways that are evolutionarily conserved (18). Extracellular 
virions are recognized via Toll-like receptors present on the cell surface and within 
endolysosomal compartments. These receptors were first identified in Drosphila and are 
now recognized as the canonical pathogen recognition system in all metazoans (53). 
Cytoplasmic pattern recognition receptors, originally identified in plants (36), also act as 
intracellular pathogen detectors. Yet another intracellular pattern recognition system 
responsible for the degradation of viral dsRNA genomes or replication intermediates is 
the RNA interference (RNAi) pathway (31). Recently, autophagy, another ancient and 
conserved intracellular pathway, has also been implicated in innate immunity and 
pathogen destruction ((16), (21), (30), (34), (39) and (44)). 
Autophagy was first genetically characterized in yeast as a response to starvation 
and is the process by which cells degrade cytoplasmic components, including organelles 
for recycling ((23), (24), (25) and (38)). Macroautophagy, which will be referred to as 
autophagy throughout this article, occurs through the de novo formation of double-
membraned vesicles called autophagosomes that envelop cytoplasmic regions, which 
mature and grow, and subsequently fuse with the lysosome for degradation of the 
internalized cytoplasmic contents. Autophagy is involved in a plethora of processes, 
including the removal of damaged organelles and intracellular protein aggregates, 
turnover of long-lived proteins, and cell death (37). Autophagy is required both for 
normal development and survival from nutrient depravation. For these processes, it has 
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been shown that autophagy is controlled by the phosphatidylinositol 3-kinase (PI3K)-
Akt-signaling pathway. Activation of the signaling pathway inhibits autophagy, whereas 
the loss of signaling through this cascade relieves the negative repression of target of 
rapamycin (TOR) kinase on Atg1, an essential upstream component of the autophagy 
pathway (51). Therefore, there is a direct link between nutrient availability and 
autophagy. 
In mammalian systems, autophagy was recently shown to be important in innate 
immune defense against intracellular pathogens (30). Studies on bacterial pathogens have 
revealed that some bacteria are cleared from the cytoplasm by autophagy ((2), (16), (33), 
(39), (40) and (50)). There have also been studies implicating autophagy in antiviral 
defense. For example, many viruses can be observed inside of autophagic compartments, 
including herpes simplex virus 1 (HSV-1) and Sindbis virus ((49) and (52)). Moreover, 
data suggest that beclin 1 (the human homolog of Atg6), perhaps via autophagy, restricts 
viral encephalitis induced by both HSV-1 and Sindbis ((32) and (41)). In plants, 
autophagy prevents the spread of cell death during the hypersensitive response, which 
restricts viral replication (34). However, it has not been established that autophagy itself 
is sufficient to control the replication of these viruses or whether there are other facets of 
activated pathways, such as cell death, that are affecting viral growth. Given the 
potentially critical role of autophagy in defending from infection and the fact that little is 
known about intrinsic antiviral mechanisms, we set out to determine whether autophagy 
can directly control viral replication in the genetically tractable organism Drosphila 
melanogaster. Drosphila has no acquired immune system, relying only on innate systems 
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to combat pathogens ((10) and (28)). This simplified immune system allows us to test the 
role of innate factors in isolation. Here, we showed that autophagy controlled vesicular 
stomatitis virus (VSV) replication in both cultured Drosphila cells and adult flies. VSV 
infection via the surface glycoprotein was sensed by flies, and this, in turn, activated 
autophagy independently of viral replication. Increased autophagic activity was mediated 
by repression of the nutrient-signaling cascade, which alleviated repression of autophagy, 
activating the antiviral program. This pathway was critical to the control of viruses 
because the loss of autophagy converts a nonpathogenic VSV infection into a lethal one. 
 
MATERIALS AND METHODS 
Cells, antibodies, and reagents. Drosphila S2 cells were grown and maintained as 
described in Schneider's media supplemented with 10% FBS (JRH), 
penicillin/streptomycin, and glutamine (9). BHK21 cells were maintained in DMEM/10% 
FBS (Sigma), penicilin/streptomycin, and glutamine. Antibodies were obtained from the 
following sources: anti-GFP (Invitrogen; different lots have different background bands), 
anti-tubulin (Sigma), anti-VSVG (gift from R. Doms), anti-VSVM (gift from D. Lyles 
and R. Hardy),and anti-phospho-Akt and anti-total Akt (Cell Signaling). Polyclonal 
rabbit Anti-Atg8 was generated against peptide (FDKRRAEGDKIRRKYPDR) and 
affinity purified by ProSci. Fluorescently labeled secondary antibodies were obtained 
from Jackson Immunochemicals, and other secondary antibodies were obtained from 
Amersham. Additional chemicals were obtained from Sigma. 
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Virus and viral components. VSV-eGFP (a kind gift from J. Rose) was grown in BHK 
cells as described (43). VSV was UV inactivated as described (17). Viral RNPs were 
purified as described (15), and the viral RNA was purified from the RNP with Trizol 
following the manufacturer's protocol. To generate VSV-G VPs, we transfected 293Ts 
with pVSV-G (Invitrogen) by using Fugene HD following the manufacturer's protocol. 
Supernatant was clarified, ultracentrifuged through a 20% sucrose cushion, and 
resuspended in PBS. 
 
RNAi and infections. dsRNAs for RNAi were generated and used for RNAi for 3 days 
as described (8). Amplicons used are described at http://flyrnai.org. Cells were passaged 
into serum-free media supplemented with dsRNA at 250 ng/20,000 cells. After 1 hr, 
complete media was added. After 3 days, cells were infected with the indicated viral 
inoculum and assayed at the indicated time point postinfection. 
 
Immunofluorescence. Cells were processed for immunofluorescence as previously 
described. In brief, cells were fixed in 4% formaldehyde/PBS, washed in PBS/0.1% 
Triton X-100 (PBST) twice, and blocked in 2% BSA/PBST. Primary antibody was 
diluted in block and incubated overnight at 4°C. Cells were washed three times in PBST 
and incubated in secondary antibody for 1 hr at room temperature. Cells were 
counterstained with Hoechst 33342 (Sigma) and imaged with an automated microscope 
(ImageXpress Micro). Three wells per treatment and three sites per well were collected. 
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Quantitation was performed with automated image analysis software (MetaXpress). 
Experiments were performed at least three times. 
Drosphila S2∗ cells were transfected with pMT-Gal4 and UAS-GFP-LC3 by 
using Effectene (QIAGEN) per the manufacturer's protocol. After 2 days, the cells were 
induced with 500 uM CuSO4, and 24 hr later, the cells were either infected or uninfected 
at an MOI = 30 or transfected with Flag-RAN along with viral RNA or RNP. After 20 hr, 
the cells were fixed, counterstained with Hoechst 33342, and processed for fluorescence 
microscopy. More than 150 cells per treatment were counted for each experiment. 
Hemocytes of the indicated genotype were obtained by dissection of third-instar 
larvae in complete Schneider's media. Fifteen larvae were pooled for each of two 
independent experiments. Cells were either uninfected or infected with VSV (MOI = 30), 
fixed and stained with Hoechst 33342, and imaged on an inverted scope (Leica). 
For Lysotracker staining of adult flies, we dissected their abdomens in complete 
media, treated them with 100 nM Lysotracker Red counterstained with Hoechst 33342 
for 10 min at room temp, and mounted them in complete media. The dissected fat bodies 
were imaged on an inverted scope (Leica). Three animals per genotype were imaged for 
each of three independent experiments. 
 
Immunoblotting, Northern blots, and titers. Cell or flies were collected at the time 
points indicated. The cells or flies were lysed in radioimmunoprecipitation assay (RIPA) 
buffer supplemented with a protease inhibitor cocktail (Boehringer). Samples were 
separated by 10% SDS-PAGE and blotted as previously described (9). For northern blot 
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analysis, cells or flies were lysed, and total RNA was extracted with Trizol (Invitrogen) 
according to the manufacturer. Ten micrograms of total RNA was run on a 1% gel and 
transferred to Hybond N+ nylon, and a radiolabeled probe was generated from the 
indicated gene. Experiments were performed at least three times independently. For 
titering, cells were collected, freeze thawed, and titered on BHK21 cells. Flies were 
crushed in DMEM/10% FBS and titered on BHK21 cells. 
 
Electron microscopy. Cells were pretreated with the indicated dsRNA for 3 days where 
indicated. Next, the cells were infected at an MOI = 5 for 20 hr and fixed in 2% PFA/2% 
glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4) for 1 hr at room temperature, 
postfixed in 2% osmium tetroxide in 0.1 M sodium cacodylate, and enbloc stained with 
2% aqueous uranyl acetate in maleate buffer (pH 5.2) for 30 min at room temperature. 
After dehydration in a graded ethanol series, cells were removed from the dish in 
propyleneoxide embedded in Epon 812. Ultrathin sections (∼70 nm) were mounted on 
mesh copper grids, stained with 2% uranyl acetate in acetone followed by bismuth 
subnitrite, and examined in a FEI-Tecnai T12 electron microscope; digital images were 
collected with Gatan CCD camera at a primary magnification of 2100×. The number of 
intracellular organelles was measured by randomly counting at least 20 cells per 
treatment per experiment. At least two independent experiments were performed for each 
comparison. Data were analyzed and plotted by using R (http://www.R-project.org). 
Significance was assessed with a Wilcoxon test. 
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Adult infections. All flies were obtained from the Bloomington stock center unless 
stated otherwise and were maintained on standard medium at room temperature. Flies 
carrying UAS-Atg12IR or UAS-Atg7IR (gift of T. Neufeld) or UAS-Atg18IR (VDRC) 
were crossed to Actin-GAL4/+ flies at room temperature. Flies wild-type (w1118), UAS-
PTEN, UAS-Δp60 (gift of M. Birnbaum), or UAS-Akt IR (VDRC) were crossed to heat 
shock GAL4. Heat shock PTEN flies were crossed to Atg1 heterozygous flies 
(Atg1[00305]). On the day of injection, the progeny were heat shocked at 37°C for 1 hour 
and shocked every 2 days throughout the experiment. The 4- to 7-day-old adults of the 
stated genotypes were inoculated with VSV-GFP as previously described (9). Groups of 
at least 20 flies were challenged for mortality studies, and a log-rank test was used to 
determine significance. Insulin (1 mg/ml) was injected in the presence or absence of 
VSV-GFP. Flies were processed at the indicated time point postinfection. Flies carrying 
UAS-eGFP-huLC3 were crossed to Hemolectin-Gal4 to drive expression in hemocytes 
((14) and (46)). 
 
RESULTS 
VSV infection of Drosphila cells. We first characterized infection of Drosphila cells 
with VSV. VSV is the prototypical member of the nonsegmented negative sense RNA 
virus family and is transmitted to cattle by insects ((29) and (42)). This virus infects and 
spreads between arthropods and mammals yet is controlled by the immune system of 
each, resulting in little mortality in either host. To study mechanisms of defense against 
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this virus, we challenged Drosphila S2 cells with VSV that expresses a GFP reporter 
(VSV-GFP) upon successful replication (43). 
We found that VSV-GFP replicates in Drosphila cells in a dose-dependent 
manner. New viral antigens were detected by 20 hr after infection as measured by GFP 
production as well as the production of the viral glycoprotein VSV-G (Figure A-1A) (8). 
We also monitored viral replication with immunoblot analysis to detect the production of 
viral antigens. Whole-cell lysates from cells infected with increasing multiplicities of 
infection (MOI) were examined with an antibody against GFP or VSV-M (Figure A-1B). 
Thus, we can monitor a dose-dependent increase in viral infection with both assays. 
We also determined whether VSV productively infects Drosphila cells. To this 
end, we monitored the production of new viral progeny. Cells were infected with 
increasing amounts of virus, and 24 hr after infection, the amount of virus produced was 
measured by plaque assay on mammalian cells, demonstrating a full replication cycle in 
Drosphila cells (Figure A-1C). Thus, VSV productively infects Drosphila cells, 
generating virus that is infectious to mammalian cells. 
 
Autophagy controls viral infection in cultured cells. Drosphila has homologs of 11 
yeast autophagy-related genes, and many of these have been confirmed to be required for 
autophagy in flies during development or starvation (48). To test whether loss of the 
autophagy pathway affects viral replication in tissue culture cells, we generated dsRNAs 
against three of these highly conserved genes previously shown to be involved in 
autophagy in flies (Atg5, Atg8a, and Atg18) (48). Three different genes were tested in 
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order to rule out off-target effects of the dsRNAs, as well as to confirm that effects 
observed are due to the autophagy pathway rather than an unrelated pathway or process 
affected by any individual RNAi reagent. To deplete the proteins, we treated cells with 
dsRNA for 3 days and then challenged the cells with VSV-GFP. We used automated 
imaging and analysis to monitor infection. With this assay, we observed a substantial 
increase in the percentage of infected cells by knocking down each autophagy-related 
gene (Figure A-2A). Semiquantitative RT-PCR and RT-qPCR were used to demonstrate 
that treatment with dsRNAs leads to a depletion of the cognate mRNA (Figure A-S1). 
The increase in viral replication measure by fluorescence was verified biochemically; 
cells were depleted for Atg5, Atg8a, or Atg18, infected with VSV, and probed by 
immunoblot for GFP (Figure A-2B). We observed an increase in the amount of GFP in 
the autophagy-related RNA-depleted cells. 
To further validate that the autophagy pathway as a whole is required for the phenotype, 
we tested additional conserved autophagy genes including Atg1, Atg2, Atg4, Atg6, Atg7, 
Atg8b, or Atg9. Cells were treated with the indicated dsRNA for 3 days and then infected 
with VSV. By using microscopy and automated image analyses, we quantified the 
percentage of infected cells across four independent experiments and normalized the 
infection to untreated cells. When compared to the nontargeting control dsRNA (β-gal), 
we observed a significant increase in VSV infection upon depletion of autophagy genes 
(Figure A-2C). We also found a similar increase in viral titers produced in cells depleted 
for autophagy genes (Figure A-2D). Altogether, these data demonstrate that autophagy 
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Figure A-1. VSV infects Drosphila cells. (A) Schneider cells were infected with VSV-
GFP at the indicated multiplicity of infection (MOI) for 20 hr. Cells were processed for 
immunofluorescence and imaged with an automated microscope (ImagXpress Micro). 
Infected cells express GFP and the viral glycoprotein VSV-G and are counterstained with 
Hoechst 33342 to observe nuclei. (B) Viral antigen production at the indicated MOI at 24 
hr after infection was measured by immunoblot against the virally produced antigen GFP 
or the cellular control tubulin. These data show a representative experiment; similar 
findings were made in at least three repetitions. (C) Viral titers from cells infected with 
the indicated MOI of VSV at 24 hr postinfection. These data show a representative 
experiment; similar findings were made in at least two repetitions. 
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controls viral replication, consistent with its playing an antiviral role in cultured cells. 
 
VSV infection activates autophagy in cultured cells. The finding that autophagy 
inhibits VSV replication suggests that autophagy might be induced by VSV infection of 
cells. Autophagy is routinely monitored by three assays: electron microscopy, fluorescent 
GFP-LC3 punctae, or as lipidated LC3 by immunoblot (22). We first monitored 
autophagy by electron microscopy. This approach allows identification of intracellular 
organelles and structures and shows that virally induced compartments are of autophagic 
origin. Double-membrane vesicles that contain cytoplasmic components or degrading 
organelles such as mitochondria are not known to arise by any other mechanism. 
Therefore, we performed electron microscopy analysis on both VSV-infected and 
uninfected S2 cells (Figure A-3A). Higher-magnification images show double-membrane 
vesicles with cytoplasmic contents or membranous contents (degrading mitochondria) 
indicative of autophagic compartments (Figure A-3B). Upon quantification of autophagic 
bodies, we found a > 2.5-fold increase in the number of autophagosomes in the infected 
cells (Figure A-3C). 
To verify that the VSV-induced vesicular structures we observed were indeed autophagic 
in origin, we tested whether Atg5 depletion by RNAi could prevent their induction. 
Indeed, we found that loss of Atg5 inhibited the induction of these autophagic 
compartments as measured by electron microscopy (Figure A-3D). Altogether, these data 
suggest that viral infection induces autophagy, which, in turn, attenuates viral replication. 
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Given that VSV infection activates autophagy, there were two possible viral inducers: 
incoming virions and viral replication products. To test whether virus replication is 
required, we challenged cells with either replication-competent or UV-inactivated virus 
and measured the effect on autophagy by using electron microscopy. UV-inactivated 
virus binds cells, undergoes endocytosis, and fuses within the endolysosomal 
compartment (11). The core, released into the cytoplasm, is replication incompetent. We 
verified that the UV-inactivated virus was indeed replication defective by fluorescence 
microscopy (Figure A-S2). By using electron microscopy, we found that both replication-
competent and UV-inactivated VSV induce autophagic vesicles (Figure A-3C). Indeed, 
quantification reveals that UV-inactivated virus induces the formation of autophagic 
bodies to a similar extent as replication-competent virus. This suggests that the incoming 
virus presents the cells with a pre-existing molecule (perhaps a pathogen-associated 
molecular pattern [PAMP]) that is sufficient to activate the antiviral program.  
During autophagy, cytosolic LC3 (LC3-I) is conjugated on its carboxyl terminus 
with phosphatidylethanolamine, forming lipidated LC3 (LC3-II), which localizes to the 
autophagic membrane. The amount of LC3-II correlates with the number of 
autophagosomes and can be monitored by immunoblot (22). In Drosphila, there are two 
LC3 homologs that are 95% similar, Atg8a and Atg8b. We developed an antibody that 
recognized the C terminus of both homologs because treatment of cells with dsRNA 
against Atg8 (dsRNA has overlap with both targets) completely abolished the signal 
(Figure A-3E). In addition, we observed an increase in the production of Atg8-II 
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Figure A-2. Autophagy is antiviral in Drosphila cells. (A) S2 cells were pretreated with 
dsRNA against control dsRNA (luciferase) or the autophagy genes Atg5, Atg8a, or Atg18 
for 3 days and then infected (MOI = 1) for 20 hr and processed for immunofluoresence 
and imaged as above. Infected cells express GFP, and the percent infection is calculated 
with automated image analysis (MetaXpress) from three wells, with three sites per well. 
Loss of autophagy genes significantly increases VSV infection (p < 0.05). (B) Depletion 
of autophagy genes increases the production of viral antigens by immunoblot. Cells 
pretreated with the indicated dsRNAs were infected (MOI = 0.1) and processed for 
immunoblot at 24 hr after infection. Viral antigens were measured by anti-GFP and 
normalized to the control protein tubulin. These data show representative experiments; 
similar findings were made in at least three repetitions. (C) Depletion of additional 
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autophagy genes by RNAi leads to an increase in the percent infection as compared to 
control dsRNA. Mean ± SD are shown for four independent experiments as the fold 
effect compared to control dsRNA (MOI = 0.1–0.25, 24 hr postinfection); ∗p < 0.05, 
Student's t test. (D) Viral titers of cells pretreated with the indicated dsRNAs at 48 hr 
postinfection with an MOI = 0.1. Data are presented as the mean ± SD fold change from 
control treatment of four averaged experiments; ∗p < 0.01, Student's t test.  
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upon starvation, validating our antibody (Figure A-3F). Next, we tested whether infection 
with wild-type or UV-inactivated virus induced the production of Atg8-II. Indeed, we 
observed marked induction of Atg8-II upon treatment with both replication-competent 
and replication-incompetent virus (Figure A-3F). 
 
VSV induces autophagy as measured by GFP-LC3 punctae formation. To further 
study the role of autophagy in VSV infection, we took advantage of an assay that depends 
on the translocation of the autophagosome protein LC3 (Atg8) from the cytosol (diffuse 
distribution) to newly formed autophagosomes, which appear as bright cytoplasmic 
punctae (20). GFP-LC3 is an autophagosome-specific membrane marker detected in 
punctae upon autophagosomes induction in both mammalian and Drosphila systems ( 
(46), (48) and (57)). This assay allows us to monitor the induction of autophagy cell by 
cell. We expressed this GFP-tagged LC3 (GFP-LC3) in cultured cells and found that 
there is diffuse cytoplasmic staining (Figure A-4A). However, upon infection with either 
wild-type or UV-inactivated virus, we observed a significant increase in the percentage of 
punctae-containing cells (Figure A-4B). Moreover, we found that there was also an 
increase in the number of punctae per cell upon infection with either wild-type or UV-
inactivated VSV (Figure A-4C). Lastly, we tested whether the activation of autophagy 
was cell autonomous. To this end, cells expressing GFP-LC3 were uninfected, infected, 
or infected at a multiplicity of infection such that 30% of the cells were VSV-M+. Next, 
we quantified the percentage of cells with punctae that were either VSV+ or VSV−. We 
found that only the infected cells had an increase in GFP-LC3 punctae (Figure A-4D). 
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Together, the combination of electron microscopy, the induction of Atg8-II, and GFP-
LC3 punctae formation shows that VSV infection, in the absence of viral replication, led 
to a robust, cell-autonomous increase in autophagy in Drosphila cells. 
 
The viral glycoprotein, VSV-G, induces autophagy. The VSV virion is largely 
composed of: the viral RNA genome; the proteins that are bound to the viral RNA that 
makes up the RNA-nucleoprotein complex (RNP); matrix proteins associated with the 
nucleocapsid; and the membrane-bound surface envelope spike glycoprotein that extends 
from the viral membrane. We set out to determine which component of the virion is the 
PAMP that is recognized by Drosphila cells, leading to the induction of antiviral 
autophagy. To this end, we purified virions from which we isolated the RNP and the viral 
RNA (15). Because VSV is a negative-strand RNA virus, the naked nucleic acid is not 
capable of initiating an infection in the absence of the viral proteins that make up the 
RNP (VSV proteins: N, P, and L). We verified that the purified RNA was nonfunctional 
and that the RNP was functional by cotransfection with a reporter to mark the transfected 
cells (Figure A-S3A). We tested whether cells transfected with the viral RNA or RNP 
induced autophagy as measured by GFP-LC3 punctae formation and found that neither 
PAMP induced autophagy with this assay (Figures A-4E and A-4F). 
 Next, we set out to test whether the viral glycoprotein VSV-G could induce 
autophagy. To purify VSV-G-containing vesicular particles (VPs) devoid of any other 
viral component, we either mock transfected or transfected 293T cells with VSV-G. 
VSV-G alone is sufficient to induce blebbing and the formation of VPs that are 
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Figure A-3. VSV infection activates autophagy independent of replication. (A) VSV 
infection induces autophagosome formation as measured by electron microscopy. 
Representative images are shown for cells that are either uninfected or infected at an MOI 
= 5 at 20 hr after infection. (B) Higher-magnification images of autophagosomes in VSV-
infected cells. (C) Active and UV-inactivated virus induce autophagic vesicles. Cells 
were infected with UV-inactivated VSV-GFP as above. Autophagic bodies were counted 
for at least 20 cells from each treatment and presented as a notched box plot. The 
horizontal dark line represents the median for each category. The box represents the 
interquartile range, and the whiskers encompass the most extreme data values. The 
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notches represent a confidence interval for the median, and nonoverlapping notches 
indicate different medians at the 5% significance level. There is a significant difference 
between uninfected and infected or UV-virus infected (∗p = 9.0e−5 and p = 3.7e−3, 
Wilcoxon test), respectively. However, there is no significant difference in the number of 
autophagosomes per cell between infected and UV-virus infected (p = 0.22, Wilcoxon 
test). (D) The induction of autophagic vesicles by VSV is Atg5 dependent. S2 cells were 
pretreated with either control (LacZ) or Atg5 dsRNA for 3 days and infected with VSV-
GFP at an MOI = 5 for 20 hr. Autophagic bodies were counted for 35 cells from each 
treatment and presented as a notched box plot as described in (C). There is a significant 
difference between control and Atg5-depleted cells (∗p = 1.2e−07, Wilcoxon test). These 
findings were observed in at least two independent experiments. (E) Immunoblot analysis 
of cells treated with control dsRNA or dsRNA against Atg8 (Atg8a and Atg8b). Atg8 is 
observed in resting cells (Atg8-I, ∼16 kD). (F) A smaller form of Atg8 is induced in cells 
that are serum starved or cells that are infected with VSV or UV-inactivated VSV (Atg8-
II, ∼14 kD). These data show representative experiments; similar findings were made in 
at least three repetitions. 
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infectious and have no other viral component ((1) and (45)). We purified the VPs and 
found that only the VPs from the VSV-G-transfected cells carry VSV-G by immunoblot 
(data not shown) and that Drosphila cells treated with the VSV-G VPs, but not the 
preparation from mock-transfected cells, were positive for VSV-G by 
immunofluorescence (Figure A-S3B). Next, we challenged cells expressing GFP-LC3 
with the purified blebs and found that treatment of cells with VSV-G+ VPs was sufficient 
to induce LC3-GFP+ punctae (Figure A-4G). Taken together, our data suggest that VSV-
G is the PAMP that is recognized by Drosphila cells. 
 
VSV infection induces autophagy both in primary cells and in adult flies. We 
extended our findings to primary cells by taking advantage of transgenic animals that 
express GFP-LC3 in larval hemocytes. Hemocytes are the Drosphila phagocytic 
macrophage-like cell type from which S2 cells are derived. We used the Gal4-UAS 
system, in which transgenes under the control of Gal4 transcription factor-binding sites 
(UAS sites) can be induced by Gal4 expression (5). This allows us to drive expression of 
the autophagosome marker GFP-LC3 with a specific hemocyte promoter, hemolectin. 
Third-instar larval hemocytes expressing GFP-LC3 (hemolectin-Gal4, UAS-GFP-LC3) 
were isolated and challenged with VSV ex vivo. In uninfected primary hemocytes, there 
is diffuse, low GFP-LC3 expression (Figure A-5A). In contrast, by 2 hr after infection, 
the hemocytes show bright GFP-positive punctae indicative of autophagosome induction 
(Figures A-5A and A-5B). This time point is prior to the initiation of viral replication, 
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further supporting the hypothesis that a preformed component of the virus, rather than 
replicating virus, is recognized by cells to induce autophagy. 
 To further demonstrate that infection induces autophagy in vivo, we infected adult 
flies with VSV-GFP and monitored autophagy with Lysotracker staining, a marker for 
acidified compartments that has been extensively used in flies ((4), (7) and (19)). With 
this assay, we found that VSV infection (GFP expression) leads to an increase in 
autophagy (Lysotracker+) in vivo (Figure A-5C). Moreover, this induction is again cell 
autonomous; only GFP+ cells were Lysotracker+. These data show that both Drosphila 
cells and animals respond to VSV infection by inducing an autophagic program.  
 
Autophagy plays an antiviral role in adult flies. To determine whether autophagy also 
plays an innate antiviral role in the adult organism in vivo, we characterized viral 
infection of adult flies by challenging them with VSV and monitored infection. We found 
that VSV infection is nonpathogenic in adult flies as measured by mortality postinfection 
(Figure A-6A). We next set out to determine whether depletion of autophagy genes alters 
the susceptibility of flies to infection. Mutant flies were generated in vivo by driving 
expression of transgenes bearing long hairpin double-stranded RNA constructs targeting 
specific autophagy genes in vivo, leading to loss-of-function phenotypes. We crossed 
control and transgenic flies with hairpin transgenes against Atg18 (UAS-Atg18 IR), 
previously shown to be required for starvation-induced autophagy in flies, to actin-
GAL4, resulting in high levels of ubiquitous transgene expression (48). We validated that 
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Figure A-4. VSV infection induces autophagy in Drosphila cells. VSV induces 
autophagosomes as measured by LC3 relocalization. (A) Drosphila cells were transfected 
with a GFP-LC3 reporter (green). Cells were either uninfected or infected with wild-type 
VSV or UV-inactivated VSV for 24 hr, fixed, and probed with anti-VSVM (red) and 
Hoechst 33342 (blue). A representative image is shown. Arrows indicate GFP-LC3+ 
punctae. (B) The percentage of cells with punctae was counted for five experiments, and 
fold change was graphed for cells that were uninfected (blue) or cells that were infected 
with wild-type VSV (red) or UV-inactivated VSV (green). Error bars represent SD. ∗p < 
0.01, Student's t test. (C) The number of punctae per cell normalized to 100% for each 
treatment (n > 150 for each condition) quantified postinfection with either VSV or UV-
inactivated VSV. (D) The induction of GFP-LC3 punctae is cell autonomous. The 
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percentage of cells with punctae was counted for three experiments, and fold change was 
graphed for cells that were either uninfected (blue), infected (red), or uninfected in a well 
in which 30% of the cells were infected (orange). Error bars represent SD. ∗p < 0.01, 
Student's t test. (E) The percentage of punctae+ cells transfected with control (red) or 
viral RNA (blue) was counted for three experiments, and fold change was graphed. Error 
bars represent SD. (F) The percentage of punctae+ cells transfected with control (red) or 
viral RNP (blue) was counted for three experiments, and fold change was graphed. Error 
bars represent SD. (G) The percentage of punctae+ cells infected with control (red) or 
VSV-G+ VPs (blue) was counted for three experiments, and fold change was graphed. 
Error bars represent SD. ∗p < 0.01, Student's t test.  
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Atg18 is indeed depleted in these flies by semiquantitative RT-PCR and RT-qPCR 
(Figure A-S1). Whereas UAS-Atg18 IR singly transgenic flies and flies expressing a 
control dsRNA (Figure A-S4) were resistant to VSV-induced lethality, actin-
GAL4>UAS-Atg18 IR doubly transgenic flies that were depleted for Atg18 became 
sensitive to infection and succumbed to the virus (Figure A-6A). Flies depleted for Atg18 
had a normal life span and were not more sensitive to infection with Drosphila C virus 
(Figure A-S4). Together, this shows that the altered pathology of the autophagy mutant is 
specific and that this pathway is protective against VSV infection. 
We also found that the increased mortality correlates with increased viral 
replication in flies. At all time points after infection, there was a marked increase in the 
amounts of VSV antigen production, as measured by immunoblot (Figure A-6B), and 
increased virus production by plaque assay (Figure A-6C). Taken together, our data 
suggest that loss of autophagy in adult flies leads to increased viral replication, leading to 
mortality from an otherwise nonlethal infection. 
To verify that our data for Atg18 is due to an effect on autophagy and not another 
role for Atg18, we tested whether depletion of additional autophagy genes Atg7 or 
Atg12, which were previously shown to be required for starvation-induced autophagy in 
flies, also affects viral replication (48). We found that there was a significant increase in 
the amount of VSV RNA replication in animals depleted for Atg18 (Figure A-6D), Atg7 
(Figure A-6E), or Atg12 (Figure A-6F) as measured by RNA blot. We also monitored 
viral replication by immunoblot analysis of the virus-encoded GFP and again 
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Figure A-5. VSV infection induces autophagy in primary cells and in adult flies. (A) 
Primary hemocytes expressing GFP-LC3 (Hml-gal4>UAS-eGFP-huLC3, green) were 
either uninfected or infected ex vivo for 2 hr and then fixed and stained with Hoechst 
33342 to visualize nuclei (blue) by fluorescence microscopy. A representative image is 
shown. (B) The percentage of cells with punctae was counted (n > 40 for each condition). 
Error bars represent the range of two independent experiments. Increased punctae 
formation is observed in the infected cells. ∗p < 0.001, chi-square test in each 
experiment. (C) Adult wild-type flies were infected with VSV-GFP for 3 days. The flies 
were monitored for infection (GFP+) and autophagy (Lysotracker+) and were 
counterstained with Hoechst 33342 to observe the nuclei. There is increased Lysotracker 
staining in the infected cells in vivo in the animal. White arrows indicate that cells that 
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are Lysotracker+ are also GFP+. Blue arrows (merged image) show that the GFP− cells 
throughout the tissue are not Lysotracker+. These data show representative experiments; 
similar findings were made in at least three repetitions.  
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observed a significant increase in viral growth in flies depleted for the autophagy genes 
Atg7 and Atg12 (Figure A-S5). We also validated that RNAi itself does not impact viral 
replication by expressing a control dsRNA against the β-galactosidase gene and found 
that there was no effect on viral growth (data not shown). Next, we determined whether 
loss of Atg7 also had an effect on survival postchallenge with VSV. Indeed, we found 
that, whereas UAS-Atg7 IR singly transgenic flies were resistant to VSV-induced 
lethality, actin- GAL4>UAS-Atg7 IR doubly transgenic flies were more sensitive to 
infection, although it takes longer to succumb to the infection (Figure A-S4). 
Lastly, we tested whether loss of Atg18 had an effect on hemocyte numbers or 
functionality. To monitor this phagocytic cell type, we injected flies that were either 
wild-type or depleted for Atg18 with fluorescent beads that are efficiently phagocytosed 
by hemocytes, allowing for the number and activity of this cell type to be monitored (12). 
We found that there was no difference in the number of hemocytes or the level of 
phagocytic activity in the hemocytes of adult flies depleted for Atg18 (Figure A-S6). 
Taken together, we demonstrate that autophagy is induced by infection, inhibits VSV 
replication, and prevents viral pathogenesis in animals. 
 
Nutrient signaling controls autophagy during viral infection in animals. Given that 
autophagy is induced by infection, we were interested in determining which signaling 
pathway might control this antiviral response. The PI3K-Akt pathway has been 
previously shown to regulate autophagy during development and starvation. Therefore, 
we tested whether this pathway also senses VSV infection in vivo. In resting cells, 
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Figure A-6. Autophagy is antiviral in adult flies. (A) Adult flies expressing ubiquitous 
and high amounts of dsRNA against Atg18 (Actin-Gal4>UAS-Atg18IR) or sibling 
controls (+>UAS-Atg18IR) were challenged with 104 plaque-forming units (pfu) VSV, 
and morbidity was monitored as a function of time after infection. Log-rank test reveals 
that loss of Atg18 significantly increases susceptibility (p < 0.001). A representative 
experiment is shown; similar findings were made in at least three experiments. (B) Adult 
flies expressing ubiquitous and high amounts of dsRNA against Atg18 (Actin-
Gal4>UAS-Atg18IR) or their sibling controls (+>UAS-Atg18IR) were challenged with 
VSV and monitored over time for viral replication, as measured by immunoblot against 
virally produced GFP, and normalized to a cellular control protein. Asterisk indicates a 
nonspecific band. (C) Adult flies expressing ubiquitous and high amounts of dsRNA 
against Atg18 (Actin-Gal4>UAS-Atg18IR, black bars) or their sibling controls (+>UAS-
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Atg18IR, white bars) were challenged with VSV and monitored over time for viral 
replication as measured by viral titers. (D) Adult flies expressing ubiquitous and high 
amounts of dsRNA against Atg18 (Actin-Gal4>UAS-Atg18IR) or their sibling controls 
(+>UAS-Atg18IR) were challenged with VSV and monitored over time for viral 
replication as measured by RNA blot. (E) Adult flies expressing ubiquitous and high 
amounts of dsRNA against Atg7 (Actin-Gal4>UAS-Atg7IR) or their respective sibling 
controls (+>UAS-Atg7IR) were challenged with VSV and monitored over time for viral 
replication as measured by RNA blot. (F) Adult flies expressing ubiquitous and high 
amounts of dsRNA against Atg12 (Actin-Gal4>UAS-Atg12IR) or their respective sibling 
controls (+>UAS-Atg12IR) were challenged with VSV and monitored over time for viral 
replication as measured by RNA blot.  
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autophagy is repressed, at least in part, by the PI3K-signaling pathway. Akt, a key kinase 
in this pathway, has been demonstrated to control autophagy via activation of the TOR 
kinase (35). TOR is a global cell regulator that responds to nutritional conditions and 
represses autophagy via Atg1 ((27) and (47)). Inhibiting this pathway either by decreased 
inputs from extracellular ligands or by overexpression of negative regulators leads to 
decreased signaling and increased autophagy ((46) and (48)). 
To modulate this pathway and test whether the PI3K-Akt pathway controls VSV-
induced autophagy, we took advantage of a well-studied negative regulator, PTEN. 
PTEN is a phosphatase that blocks PI3K signaling by dephosphorylating PI(3,4,5)P3 
(55). Overexpression of this factor leads to an increase in autophagy in the larval fat body 
((3) and (48)). We overexpressed this gene in transgenic animals with a heat shock Gal4 
driver and found that there was no effect on fly viability (data not shown). We tested 
whether PTEN also controls autophagy in the adult fat body by using Lysotracker, a 
standard assay in Drosphila ((4), (7) and (19)). With this assay, we found that 
overexpression of PTEN induces autophagy in fat bodies of well-fed adults (Figure A-
S7). 
We then challenged flies overexpressing PTEN and thus undergoing constitutive 
autophagy with VSV and monitored viral replication. We observed a decrease in viral 
protein production compared to controls by immunoblot analysis (Figure A-7A). To 
further dissect the role of PI3K signaling in the control of VSV infection, we tested 
whether inhibition of the pathway with a different negative regulator also blocks 
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infection. We took advantage of a deleted form of p60, the adaptor that couples the 
insulin receptor to the catalytic subunit of PI3K, Dp110 (6). This deletion mutant, Δp60, 
is a variant that lacks the Dp110-binding domain, which, when overexpressed, inhibits 
the PI3K-Akt-signaling pathway similarly to the overexpressed PTEN, thereby leading to 
an increase in autophagy (48). By using the same heat shock GAL4 overexpression 
system to drive expression of Δp60, we also observed a decrease in VSV replication as 
measured by immunoblot (Figure A-7A). Together, these data indicate that inhibition of 
the PI3K-Akt pathway, which, in turn, activates autophagy, also inhibits VSV replication, 
suggesting that this pathway plays an important role in the antiviral response. 
To verify that the increase in VSV replication observed upon inhibition of the 
PI3K-Akt pathway is indeed due to activation of autophagy and not another pathway 
regulated by this signaling cascade, we performed epistasis analysis. Atg1, a conserved 
serine-threonine-specific protein kinase, is a crucial component of the autophagy 
machinery and a key regulator of autophagy. Loss of Atg1 blocks autophagy, whereas 
overexpression leads to an increase in autophagy in flies ((48) and (47)). Therefore, it is a 
limiting component of this pathway. First, we tested whether loss of one copy of Atg1 
had an effect on infection and found that this had no effect on VSV levels (Figure A-S8). 
Next, we performed the epistasis analysis in a sensitized background by crossing flies 
carrying a heat shock promoter driving expression of PTEN (heat shock PTEN) to flies 
that were heterozygous for Atg1. This allowed us to compare flies that overexpressed 
PTEN and had two copies of Atg1 to flies that were heterozygous for Atg1. We expected 
that the decreased viral replication mediated by overexpression of PTEN would be 
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attenuated in animals that had reduced Atg1 levels. We challenged these siblings and 
found that removing one copy of Atg1 relieves the PTEN-mediated repression of VSV 
replication (Figure A-7B). This experiment demonstrates that the effect of PTEN on VSV 
is mediated by an increase in autophagy. 
The previous experiments relied on overexpression phenotypes; therefore, we 
tested whether we observed a similar dependence on nutrient signaling by using a loss-of-
function strategy. Loss of Akt signaling is predicted to activate autophagy and inhibit 
VSV replication. To this end, we tested whether loss of Akt by RNAi, by using a 
previously validated transgene, would result in decreased viral replication (54). We found 
that depletion of Akt by RNAi led to a decrease in VSV replication as measured by 
immunoblot (Figure A-7C). 
Together, these data suggest that infection by VSV is sensed by flies, leading to a 
decrease in PI3K/Akt signaling, which increases autophagy and inhibits viral replication. 
However, these data do not show whether infection itself modulates this signaling 
pathway. A prediction is that VSV infection is sensed by the fly, leading to the repression 
of PI3K/Akt signaling to activate the antiviral autophagy program. We set out to test this 
hypothesis by monitoring signaling during infection. One method to monitor signaling 
through this pathway is to measure the levels of phosphorylation of Akt by immunoblot. 
We challenged the flies with VSV and compared the amounts of phospho-Akt to flies that 
were uninfected. We observed a substantial decrease in amounts of phospho-Akt in VSV-
infected animals (Figure A-7D). In contrast, total Akt protein remained constant. Thus, 
VSV infection leads to an inhibition of Akt signaling in animals.  
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DISCUSSION 
Although autophagy has been implicated in diverse processes, both normal and 
pathogenic, a role in controlling viral replication has been difficult to demonstrate 
directly in vivo and is complicated by differing requirements by distinct pathogens. With 
a new model system, we found that autophagy plays an important antiviral role against 
VSV in tissue culture cells as well as in adult flies. By modulating the pathway in vivo—
either inhibiting it with RNAi against components of the autophagic machinery or 
activating it by repressing the function of upstream members of the PI3K/Akt-signaling 
pathway—we demonstrate a reciprocal effect on viral replication: activation of autophagy 
inhibits, and inhibition of autophagy exacerbates infection. Moreover, we showed that 
infection is sensed by flies and leads to inhibition of the Akt-signaling pathway. This, in 
turn, leads to activation of the antiviral autophagic program, thereby protecting the 
animal from an otherwise lethal virus infection. 
Furthermore, our data suggest that autophagy is directly activated by VSV 
infection, most likely via the surface glycoprotein VSV-G, and thus activation does not 
require viral replication. Although VSV RNA can be recognized by the cytoplasmic 
sensors in mammals, we showed that VSV RNA was not the sensor for autophagy in 
flies. Moreover, this class of intracellular sensors has not yet been identified in 
Drosphila. Interestingly, recent work in mammalian systems indicates that VSV-G can 
also be recognized by TLR4 to activate this class of pattern recognition receptors (PRRs) 
(13). It has been observed that TLR4 signaling can activate autophagy downstream of 
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Figure A-7. The PI3K-Akt pathway controls autophagy and viral replication in 
adult flies. (A) Flies carrying a heat shock-inducible Gal4 were crossed to UAS-PTEN, 
UAS-Δp60, or control at room temperature. Progeny were collected and heat shocked at 
37°C for 1 hr on the day of infection and every 2 days after challenge. Viral replication 
was monitored over time for viral replication by immunoblot against virally produced 
GFP and normalized to cellular proteins. (B) Flies carrying a heat shock-inducible PTEN 
were crossed to flies heterozygous for a mutant Atg1 allele at room temperature. Progeny 
were collected and heat shocked at 37°C for 1 hr on the day of infection and every 2 days 
after challenge. Viral replication was monitored over time for viral replication by 
immunoblot against virally produced GFP and normalized to a cellular control protein. 
(C) Flies carrying a heat shock-inducible Gal4 were crossed to UAS-Akt IR at room 
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temperature. Progeny were collected and heat shocked at 37°C for 1 hr on the day of 
infection and every 2 days after challenge. Viral replication was monitored over time for 
viral replication by immunoblot against virally produced GFP and normalized to cellular 
proteins. (D) Flies were injected with insulin in the presence or absence of VSV. 
Phospho-Akt and Total-Akt were monitored by immunoblot. These data show 
representative experiments; similar findings were made in at least three repetitions.  
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the bacterial PAMP LPS, suggesting a link between pattern recognition by TLRs and the 
cellular antimicrobial response (56). Drosphila has nine TLRs, raising the possibility that 
this VSV-G-dependent viral recognition pathway uses this class of pattern recognition 
receptors; however, other receptors may be involved. Previous studies found that, in 
specialized antigen-presenting dendritic cells that are not competent for VSV replication, 
autophagy is required to present VSV antigens to endosomal TLR7, suggesting that 
different aspects of the autophagic pathway may modulate viral replication under 
different conditions or in specialized cell types (26). 
Autophagy has been shown to be essential for defense against a variety of 
pathogens in cell culture. Our studies suggest that VSV-G is recognized by a pattern 
recognition receptor whose activation leads to inhibition of the PI3K-signaling pathway, 
increasing autophagy and thereby blocking viral replication. Importantly, this newly 
identified antiviral pathway may play a role in the control of additional infectious agents. 
Moreover, it may be fruitful to explore pharmacological modulation of the pathway as a 
means to inhibit viral replication because there are a number of small molecule 
modulators that have been developed to regulate the PI3K-Akt-signaling pathway. 
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SUPPLEMENTAL DATA 
 
 
Figure A-S1. dsRNA against autophagy genes is efficacious both in cells and flies as 
measured either by semiquantitative RT-PCR or RT-qPCR. (A) >75% depletion of 
the cognate message as measured by semi-quantitative RT-PCR against Atg18 (orange) 
or Atg8a (green) normalized to a cellular control (clathrin heavy chain). Control dsRNA 
treated samples are set to 100%. (B) Semi-quantitative RT-PCR against Atg18 
normalized to control (clathrin heavy chain). Adult flies expressing ubiquitous and high 
level dsRNA against Atg18 (Actin-Gal4; UAS-Atg18IR) were compared to sibling 
controls (+; UAS-Atg18IR) which were set to 100%. C. RT-qPCR against Atg18 
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normalized to control (rp49) in adult flies as in B. or in cells pre-treated with the 
indicated dsRNAs.  
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Figure A-S2. Schneider Cells Were Infected with VSV-GFP (MOI=9) or UV-
Inactivated VSV-GFP (Equivalent Volume) for 20 Hours. Cells were processed for 
immunofluorescence and imaged using an automated microscope (ImagXpress Micro). 
There were no Gfp+ cells in the UV inactivated sample. 
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Figure A-S3. Purified viral components reveal that VSV G is the PAMP. (A) Purified 
VSV RNP but not VSV RNA is infectious when transfected into cells. Schneider cells 
were co-transfected with Flag-tagged RAN and either VSV RNA (left) or VSV RNP 
(right). Cells were processed for immunofluorescence with anti-FLAG (red), anti-VSV M 
(green) and nuclei (blue) and imaged. There were no VSV-M+ cells in the viral RNA 
transfected sample while >95% of the Flag+ (transfected) cells were VSV-M+. (B) Cells 
treated with VPs from VSV G transfected 293s but not blebs from mock-transfected cells 
are VSV G+ and induce GFP-LC3 punctae. Cells were transfected with GFP-LC3 and 
then treated with VPs and processed for fluorescence with GFP-LC3 (green), anti-VSV G 
(red) and nuclei (blue). 
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Figure A-S4. Depletion of autophagy in adult flies specifically impairs VSV 
susceptibility. Flies of the indicated genotypes were challenged with (A) PBS or (B) 
Drosphila C Virus (DCV) or (C) VSV. (D) VSV and monitored daily for mortality. Log 
rank test reveals that loss of Atg7 significantly increases susceptibility (p<0.05). A 
representative experiment is shown. Each challenge was repeated at least three times. 
  
	  
	  
	  
167	  
 
 
 
 
Figure A-S5. Autophagy controls VSV but not DCV infection in adult flies. 
Adult flies expressing ubiquitous and high-level dsRNA against either Atg12 (Actin-
Gal4; UASAtg12IR) or Atg7 (Actin-Gal4; UAS-Atg7IR) or their respective sibling 
controls (+; UASAtg12IR or +; UAS-Atg7IR) were challenged with VSV and monitored 
over time for viral replication as measured by immunoblot against virally produced GFP 
and normalized to a cellular control protein. There is a significant increase in VSV 
replication in flies depleted for autophagy genes measured by protein production. * 
indicates nonspecific background band. 
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Figure A-S6. Atg18-depleted flies have wild-type numbers of hemocytes that are 
functional as measured by phagocytic activity. Adult flies were injected with 0.2um 
red fluorescent beads. Three days later the flies were processed for fluorescence 
microscopy. Hemocytes are the only phagocytic cells which take up fluorescent beads, 
which can be readily visualized through the cuticle and are distributed throughout the 
abdomen. Top panels at low magnification and the indicated inset is shown at higher 
magnification to show individual cells that have taken up multiple beads. Areas of 
increased saturation in top panels are likely aggregated hemocytes. 
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Figure A-S7. Flies carrying a heat shock-inducible Gal4 were crossed to UAS-PTEN 
or control at room temperature. Progeny were collected and heat shocked at 37C for 
one hour the day before and the day of staining. Autophagy was monitored using 
Lysotracker staining to visualize the autophagosomes and counterstained with Hoescht 
33342 to observe the nuclei. There are increased acidic compartments in the fat body 
cells of well-fed flies expressing the negative regulator PTEN compared to the diffuse 
dim staining in the control fat body cells. 
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Figure A-S8. Heterozygous ATG1 mutants carry wild-type levels of VSV. Flies of the 
indicated genotypes were challenged with VSV and monitored by immunoblot at the 
indicated time post infection. 
 
 
 
